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ABSTRACT
Cancer is the second leading cause of death in the United States. Due to the increase in
exposure to cancer-causing environmental factors, the presence of chronic conditions,
and the increase in age-related mutations in normal tissue, cancer incidence is
positively correlated with age. Because of the increase in life expectancy due to
advances in medicine, the frequency of cancer incidence is expected to rise in the
future. For these reasons, devising methods to efficiently diagnose and treat cancer is
extremely important.

Effective targeting of cancer cells within tumors would allow for improvement in the
efficacy of treatment and the reduction of side effects. Tumor targeting falls into three
broad categories: passive targeting, active targeting, and physical targeting. Passive
targeting generally employs the enhanced permeability and retention effect, a
phenomenon that leads to the localization of a certain range of sizes of
macromolecules in tumor tissue due to the non-intact vasculature present in this tissue.
Passive targeting can work well to deliver some therapeutic agents to solid tumors, but
lacks targeting specificity and can therefore result in substantial targeting of healthy
tissue, especially the liver, lymph nodes, and spleen.

Active targeting relies on a much greater presence of certain characteristics, called
biomarkers, on or in cancer cells than on/in normal cells. To exploit active targeting,
therapeutic agents are conjugated to targeting moieties like antibodies, aptamers, or
small molecules that have a high affinity to these biomarkers. Active targeting has

some advantages over passive targeting, namely, higher targeting specificity.
However, one significant disadvantage of active targeting is its reliance on the
overexpression of biomarkers in cancer cells: tumor tissue is very heterogeneous, with
varying levels of expression across the cancer cell population; additionally, these
biomarkers are usually present in normal tissue, leading to the undesirable targeting of
healthy tissue.

Physical targeting relies on a difference in physical properties, such as temperature,
oxygenation, or pH, between normal tissue and cancer tissue. These physical
characteristics can be more universal to tumor tissue, regardless of the tissue
vasculature or biomarker expression. Physical targeting offers specificity advantages
over passive targeting, and offers advantages over active targeting based on the
universality and specificity of the targeted physical traits, compared to the broader,
varying levels of expression of active-targeted biomarkers.

It has been known for over fifty years that tumor tissue undergoes acidification due to
a switch in metabolic pathway resulting in the production of high levels of lactic acid
and protons, a phenomenon known as the Warburg effect. In addition, cancer cells
overexpress certain membrane proteins that catalyze reactions in the blood that result
in further acidification. Although cell surface acidity is a feature that is ubiquitous to
solid tumors, as a biomarker it has been greatly overlooked in favor of expressed traits
like growth factors, protein receptors, and antigens.

pH Low Insertion Peptides (pHLIPs) comprise a family of pH-sensitive peptides, and
sense and target the acidity present at the surface of cancer cells. pHLIPs can be
conjugated to many different types of imaging and therapeutic agents, and, targeting
the physical characteristic of pH, are able to selectively deliver these agents to tumor
tissue while avoiding normal tissue. The mechanism of action of pHLIP is based on
membrane-associated folding triggered by low pH: at low pH, a high concentration of
protons results in the protonation of certain residues in pHLIP which leads to an
increase in peptide hydrophobicity and drives the peptide to partition into the
hydrophobic core of the membrane; here, pHLIP folds into a transmembrane helix,
leaving one terminus in the extracellular space while the other terminus is translocated
across the cell membrane into the cytoplasm.

The main goal of this work was to optimize various pHLIPs and to evaluate the utility
of pHLIP conjugates in the selective delivery of imaging and therapeutic agents used
in specific medical applications: namely, for PET imaging and for the intracellular
delivery of toxic cargo. Over the course of this work, we introduced several new
imaging and drug-delivery conjugates based on existing pHLIP variants, as well as
several new drug-delivery conjugates based on novel pHLIP variants. An emphasis
was placed on the biophysical characterization of new peptides and conjugates, and
the measurement of the ability of drug-laden conjugates to induce cell death in in vitro
assays in a pH-dependent manner. Aside from these points upon which we place
special emphasis, the effects of physiological levels of free divalent cations on protein
folding were investigated via biophysical measurements for the first time.
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PREFACE
This dissertation is written in “Manuscript” format, using the Thesis/Dissertation
template of the University of Rhode Island. There are three manuscripts included in
this dissertation, each of which comprises a chapter. The tables and figures of each
manuscript are listed under the corresponding chapter in the list of tables and figures.

The results of our studies presented in the first two chapters were published in the
following papers:
1. Wyatt LC, Lewis JS, Andreev OA, Reshetnyak YK, Engelman DM.
“Applications of pHLIP Technology for Cancer Imaging and Therapy.” (2017)
Trends in Biotechnology. 35(7)653-664.
2. Demoin DW, Wyatt LC, Edwards KJ, Abdel-Atti D, Sarparanta M, Pourat J,
Longo VA, Carlin SD, Engelman DM, Andreev OA, Reshetnyak YK, ViolaVillegas N, Lewis JS. (2016) “PET imaging of extracellular pH in tumors with
64

Cu- and

18

F-labeled pHLIP peptides: A structure-activity optimization

study.” Bioconjugate Chemistry 27(9):2014-2023.

The final chapter is composed of research that has been submitted for publication:
3. Wyatt LC, Moshnikova A, Crawford T, Engelman DM, Andreev OA,
Reshetnyak YK. “New pHLIPs for the Targeted Intracellular Delivery of
Cargo Molecules to Tumors.” Manuscript submitted for publication.
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ABSTRACT
Acidity is a biomarker of cancer that is not subject to the blunting effects of clonal
selection, effects that reduce the efficacy of other biomarker technologies, like
antibody targeting. The pH (Low) Insertion Peptides (pHLIPs) provide new
opportunities for targeting acidic tissues. Through the physical mechanism of
membrane-associated folding, pHLIPs are triggered by the acidic microenvironment to
insert and span the membranes of tumor cells. The pHLIP platform can be applied to
imaging acidic tissues, delivering cell-permeable and impermeable molecules to the
cytoplasm, and promoting the cellular uptake of nanoparticles. Since acidosis is a
hallmark of tumor development, progression, and aggressiveness, the pHLIP
technology may prove useful in targeting cancer cells and metastases for tumor
diagnosis, imaging, and therapy.

2

EXTRACELLULAR ACIDITY
Acidity is a hallmark and predictor of tumor development and progression
Even in the presence of oxygen, cancer cells use the anaerobic pathway more
than normal cells do, a phenomenon known as the Warburg effect [1-3]. Normally,
cell metabolism occurs through a low rate of glycolysis followed by oxidation of
pyruvate in the mitochondria, whereas anaerobic metabolism is associated with a high
rate of glycolysis and lactic acid fermentation [4]. Protons are a byproduct of both
pathways; however, when cells use glycolysis and lactic acid fermentation at a high
rate, excess lactate and protons are produced. In order to maintain homeostasis, a cell
must keep its intracellular pH at the physiological level, around pH 7.2-7.4. If the pH
inside the cell drops, the cell will pump excess acidity into the extracellular space to
maintain physiological pH levels in the cytoplasm. Additionally, cancer cells
overexpress surface carbonic anhydrases (CAIX and CAXII), which catalyze the
transformation of carbon dioxide and water into carbonic acid (bicarbonate and
protons) [5-7]. Thus, excessive amounts of acid and protons accumulate in the
extracellular space, especially in poorly perfused tumor regions, reducing the pH of
the extracellular space and leading to tumor acidification [8, 9].
Not only is acidity a hallmark of tumor development, but acidity also facilitates
tumor growth [10]. The acidification of the healthy tissue surrounding a tumor leads to
tissue remodeling that allows for local invasion. Studies in which the pH of the surface
of tumors was monitored showed that the regions of the highest tumor invasion (see
Glossary) corresponded to areas of highest acidity [10]. Therefore, targeting the most
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acidic regions of tumors is especially beneficial because the most acidic regions are
the most aggressive [11].

Bulk extracellular pH versus cancer cell surface pH
Recent studies using a fluorophore with a pH-dependent emission spectrum
have shown that the pH in the vicinity of the plasma membrane of cancer cells is about
0.3-0.7 pH units lower than the bulk extracellular pH [12]. In experiments in vitro,
where the pH of the solution in which the cancer cells are growing (bulk pH) is
maintained at pH 7.4, the cell surface pH for highly metastatic cells has been shown to
be around pH 6.7. In three-dimensional tumor models, ex vivo mouse tumor tissue, and
live animals, the cancer cell surface pH has been shown to be as low as pH 6.0. Thus,
cancer cells have a “crown of acidity” near their cell surfaces. The pH becomes less
acidic with distance from the cell surface and, therefore, the bulk extracellular pH can
be relatively high, especially in well-perfused regions. However, the cell surface pH
always remains low (acidic). The bulk extracellular pH correlates with perfusion,
while the cell surface pH is expected to be less dependent on tumor tissue perfusion,
and to be a predictive marker of tumor development and progression, since more
aggressive tumor cells are more acidic.

pHLIP TECHNOLOGY
Peptides of the pHLIP family and their mechanism of action
The pH (Low) Insertion Peptide (pHLIP®, see Glossary) was derived from the
C-helix of the protein bacteriorhodopsin, and originally was called the BRC peptide
4

[13]. The salient feature of a pHLIP is its ability to sense the pH in the vicinity of the
plasma membrane and to spontaneously form a helix and insert across the membrane
when the extracellular environment is acidic (Figure 1) [14, 15]. Numerous
modifications have been made to the primary sequence of pHLIPs to evaluate and tune
the properties of the interaction of the pHLIP with the cell membrane [16]. These
modifications include testing a pHLIP consisting entirely of D-amino acids against
one containing entirely L-amino acids (no change was observed) [17]; truncating and
reversing the wild-type (WT) pHLIP sequence, and in so doing introducing new
pHLIP variants [18, 19]; swapping some or all aspartic acid residues for glutamic acid
residues [16, 20, 21], positively-charged lysine residues [18, 22-30], or the
protonatable non-standard amino acids such as γ-carboxyglutamic acid and αaminoadipic acid [31]; and the de novo design of a pHLIP variant [32].
Variation of the WT pHLIP sequence led to novel pHLIPs, such as Variant 3
(Var3), with significantly improved tumor targeting properties [18, 28, 33-35]. The
overall features of the pHLIP peptide sequences are still present in all variants: a
middle region interspersed with a combination of hydrophobic residues and residues
that are negatively charged at physiological pH but become neutrally charged at low
pH, and hydrophilic flanking regions, with the membrane-inserting C-terminus (in
most sequences) containing a few additional protonatable residues (Box 1) [9, 36-38].
Var3, in particular, has a truncated membrane-inserting end, which leads to its faster
partitioning into the cell membrane to form a transmembrane helix. This variant
exhibits the highest difference between the Gibbs free energies of its interaction with
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the membrane at low and high pHs, which ensures pH-dependent preferential targeting
of the cancer cells [18].
The mechanism of action of all peptides in the pHLIP family is well
understood: membrane-associated folding is triggered by the protonation and increase
in hydrophobicity of the peptide when exposed to acidic environments (Figure 2) [15,
19, 22, 39, 40]. At physiological pH, a population of pHLIPs mainly exists as an
equilibrium between two states: a solvated state in which the pHLIP adopts a
conformation with little secondary structure, and a state in which the pHLIP remains
disordered and is adsorbed to the surface of the cell membrane [15]. At low pH, an
increased concentration of protons results in the protonation of negatively charged
residues at key locations in the peptide. This protonation increases the overall
hydrophobicity of the pHLIP, resulting in its folding to form a helix that partitions
across the bilayer as a transmembrane helix. The inserted peptide leaves its Nterminus in the extracellular space while the C-terminus is translocated across the
membrane into the cytoplasm. The lipid composition of the cell membrane can
contribute to modulation of the binding and insertion into the membrane of a pHLIP
[20, 41, 42].
It is important to distinguish between the pHLIP family, which consists of
membrane-inserting peptides, and cell-penetrating peptides (CPPs) or amphipathic
pore-forming peptides. CPPs and pore-forming peptides have entirely different
mechanisms of action and different biological performance; they are not part of the
pHLIP family.

6

Targeting extracellular acidity
Targeting cancer cells by exploiting extracellular acidification should be
compared with other targeting approaches, which are commonly based on the presence
of growth factors or tumor antigens. A problem in targeting these kinds of specific
features is that the cancer cell population, both between tumors and within an
individual tumor, is extremely heterogeneous and very adaptable [43]. The potential
for successfully treating tumors that do not express or exhibit limited expression of the
targeted growth factor or antigen is low, and, even in treatment-responsive tumors,
minority populations of cancer cells can undergo clonal selection and eventually regrow into a treatment-resistant phenotype. Subsequent treatments will either have
limited efficacy or be entirely ineffective. Additionally, these types of targeting
methods have the potential to severely damage healthy tissues where the growth factor
or antigen might also be present. Therefore, targeting tumor acidity, a physical
characteristic that is not only found across an entire tumor but is found in tumors of all
sizes, including metastases, could have advantages over targeting methods based on
characteristics that are found only in some tumors or some cancer cell populations [44,
45].
Acidity is produced not only by cancerous tissue, but also by any tissue that is
experiencing hypoxia: the lack of oxygen in the tissue triggers cells to switch to a high
rate of the anaerobic, glycolytic energy production pathway, consequently resulting in
acidification. pHLIPs have been shown to target infections in lungs [46], inflammatory
arthritis [22], and ischemic myocardium, a consequence of heart disease, and could be
used for diagnosis and treatment thereof [26]. It is also possible that pHLIPs could be
7

used as targeted treatment in ischemic strokes. In contrast to diseased tissue, healthy
tissue is typically not associated with increased acidity except in the gastrointestinal
tract and kidney, the pHs of which might be regulated by the implementation of a
special diet or supplementary drinks if their acidity proves problematic.
In contrast to other pH-sensitive agents that sense bulk pH, members of the
pHLIP family of peptides bind to cell surfaces at all pH values and therefore sense pH
at the surfaces of cancer cells, where pH is the lowest, further accentuating the pH
sensitivity of the peptides. The pH-dependent behavior and inserted conformation of
pHLIPs make them useful for delivering cargo inside cancer cells (by attaching the
cargo to the inserting end of the peptides) or for tethering cargo to the cell membrane
(by conjugating to the non-inserting end of the peptides) [9]. Additionally, small-angle
X-ray scattering experiments have shown that pHLIPs do not form oligomers larger
than tetramers, even at very high concentrations [47], a useful property for drugs to be
used intravenously, as the local concentration at the injection site is generally much
higher than the drug concentration when it reaches the target area, and it is crucial that
the drug does not aggregate upon injection. These basic features give rise to a wide
variety of possible applications in diagnostic imaging, fluorescence guided surgery,
the intracellular delivery of small molecules like toxins and gene regulation agents, the
delivery of proteins to the surfaces of cells, and the delivery and uptake enhancement
of nanoparticles.

APPLICATIONS OF pHLIP TECHNOLOGY
Diagnostic nuclear imaging
8

Positron emission tomography (PET) and single-photon emission computed
tomography (SPECT) are imaging techniques that rely on the delivery of radioactive
imaging agents to targeted tissue. One of the main challenges in PET/SPECT imaging
is to obtain images of target tissue that contrast highly with the image background,
motivating the use of a targeting agent. When a radionuclide is conjugated to the noninserting terminus of a pHLIP (Figure 3A), the resulting construct not only targets
tumor tissue very well, but also remains securely in the tumor long enough to allow
the excess, non-inserted construct to clear from normal tissues, resulting in higher
contrast images [17, 23, 25, 29, 33]. Success has been seen using the radioisotopes 18F
(9 ± 2 %ID/g at 4 h p.i.) and 64Cu (19 ± 2%ID/g at 24 h p.i.) conjugated to Var3 [33].
These constructs are in the process of clinical translation as novel nuclear imaging
markers of diseased tissue acidity.

Fluorescence-guided surgery and ex vivo imaging
Fluorescence-guided surgery utilizing pHLIP technology could ease the
challenges of tumor resection, such as visualization of all cancerous lesions, including
flat lesions, ultimately reducing the number of surgeries that result in positive
margins. These features could improve surgery outcomes and reduce tumor
recurrences. Excellent targeting and labeling by different fluorescent pHLIPs of
primary tumors and sub-millimeter-sized metastatic lesions has been demonstrated on
various tumor models, including transgenic breast, prostate, melanoma and pancreatic
mice models [11, 24, 28, 34, 35, 48].
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Excellent staining and visualization of urothelial tumors has been observed in
excised human bladders using an ICG pHLIP imaging agent [48]. This imaging agent
marked high-grade urothelial carcinomas, both muscle-invasive and non-muscleinvasive lesions, and, most importantly, flat lesions, which are the most difficult to
identify and commonly necessitate further surgery. Carcinoma in situ was accurately
diagnosed in eleven cases, whereas only four cases were identified using white light.
The sensitivity and specificity of targeting by the ICG pHLIP imaging agent were
found to be 97% and 100%, respectively, excluding staining of necrotic and
previously treated tissue.
Another application of fluorophore-labeled pHLIPs is the ex vivo staining and
imaging of biopsy samples or tissue after surgical resections. Fluorophore-conjugated
pHLIPs have shown utility in accurately identifying head and neck cancer, proving
their potential to be useful tools for the early identification and evaluation of dysplasia
and neoplasia [49, 50]. In these studies, both the normal and suspect biopsy samples
were stained ex vivo with Alexa Fluor647 pHLIP. Imaging was performed before and
after staining, and the ratio of intensity increase of suspect tissue to normal tissue was
calculated; a two- to six-fold increase in fluorescence intensity ratio was observed in
cancerous tissue compared to normal tissue (with no ratio increase for the inflamed
tissue).
The conjugation of the pH-sensing fluorescent dye SNARF to a pHLIP results
in a compound that can measure pH at the surface of individual cells, which differs
greatly from the more easily and commonly measured bulk pH [12]. Currently,
approaches for cell surface pH mapping using SNARF-pHLIP in liquid and solid
10

biopsy samples are being developed, which might result in an opportunity to get
information about the metabolic status of tumors, ultimately aiding in the prediction of
tumor aggressiveness and the tailoring of therapy. SNARF-pHLIP might also be used
in longitudinal studies as a very useful tool in the investigation of the development and
progression of diseases.

Intracellular delivery of drug-like and polar therapeutic cargo molecules
pHLIPs translocate their C-termini into the cytoplasms of tumor cells, allowing
the intracellular delivery of therapeutic cargo molecules to treat primary tumor tissue
as well as metastases. The ability of pHLIPs to target metastases is especially
important: in cancer cases, the primary tumor is generally not the reason for poor
prognoses; more often, it is tumor invasion, unseen by traditional diagnostic
procedures, that proves fatal.
Extensive biophysical investigations, including kinetics and thermodynamics
studies, have been conducted to determine the activation energy required for the
membrane insertion/folding (as well as unfolding/exit) of pHLIPs [19-21, 39, 51].
These studies set the foundation for the development of novel approaches in drug
delivery that are based on employing the energy of membrane-associated folding and
the kinetically controlled pH-triggered translocation of cargo molecules across the
lipid bilayer of the cell membrane (Figure 3B). Cargoes can be linked to the Cterminus, for example, by including a cysteine in the pHLIP sequence and attaching
the cargo via a disulfide that is cleaved in the cytoplasm, releasing the cargo.
Following fundamental studies, numerous in vitro and in vivo investigations have
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demonstrated that pHLIPs can deliver several different payloads, such as fluorescent
dyes, toxins, drugs, peptides, and peptide nucleic acids (PNAs) [14, 52-61]. The
many molecules delivered into cells by pHLIPs can be conceptualized in two
categories: drug-like, cell-permeable molecules; and polar, cell-impermeable cargoes.
In the first case, pHLIPs might improve the pharmacokinetics and favorably alter the
biodistribution of drugs, resulting in enhanced tumor accumulation. In the second
case, pHLIPs, in addition to tumor targeting, can deliver polar molecules that cannot
cross the plasma membrane via passive diffusion.
Additionally, it is possible to tune the intracellular delivery of cargo by altering
the C-terminal sequence, by choices of the linker connecting cargo to a pHLIP, and/or
by attaching modulator molecules [52-54]. Changing the efficiency of cargo
translocation leads to a change in biological response: systematic studies in which
polar toxins are conjugated to pHLIPs via cleavable linkers of different
hydrophobicity show subtle changes in the insertion properties of the constructs and,
therefore, in the resulting cytotoxicity. Thus, depending on cargo polarity, the
translocation of cargo across cellular membranes could be optimized by the proper
selection of pHLIPs, linkers and modulator molecules.
At low pH (pH <6.5), pHLIPs promote delivery of cell-permeable therapeutic
cargoes such as the tubulin-binding toxin monomethyl auristatin E (MMAE) and the
DNA intercalator doxorubicin, and reduces the cellular entry of these cargoes into
healthy tissue at normal physiological pH [57, 58]. pHLIP MMAE conjugates have
cytotoxic effects at low pH, inhibiting cell growth by more than 90% , and targeted
triple-negative breast cancer tumors in mice [58].
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One of the most attractive therapeutic applications of pHLIPs is their ability to
deliver polar molecules. Studies have been conducted using polar cyclic toxins from
the death cap mushroom (Amanita phalloides): phalloidin, phallacidin and amanitin.
Phalloidin and phallacidin bind to F-actin, while amanitin is an inhibitor of RNA
polymerase II. All toxins, when conjugated to pHLIPs, have shown a pH-dependent
ability to induce cell death [52, 53]. α-Amanitin is the most potent cargo studied so
far, and, when conjugated to a pHLIP and exposed to cancer cells for less than two
hours, it displayed a four- to five-fold higher antiproliferative effect at low pH (pH
6.5) compared with physiological pH [54].
Also, pHLIPs have been proven to deliver peptides to interfere with the
biological action of protein receptors or to disrupt mitochondrial cellular membranes
[59, 60]. PAR1 is a protein receptor that is overexpressed in many cancer cells. A
PAR1 protein fragment was shown to be translocated across the cell membrane by a
pHLIP, where it interacted with the intracellular domain of the PAR1 receptor,
rendering the protein receptor inactive and inducing pH-dependent cytotoxicity [59].

Intracellular delivery of gene-regulation agents
There is an expectation that future therapy (including cancer therapy) will be
based on drugs that induce genetic interference in cancer cells. Efficiently modulating
gene expression inside cancer cells and either reprogramming them to be normal cells
or inducing apoptosis will be a significant breakthrough. Oncogenic microRNAs
(oncomiRs) are miRNAs whose overexpression is associated with cancer
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development; thus, it is desirable to inhibit an oncomiR, which can be achieved using
complementary synthetic RNA strands, such as PNAs [56, 62, 63].
The main obstacle to the successful use of PNA antimiRs is that they do not
cross cell membranes. pHLIPs, however, have been shown to deliver PNAs to cancer
cells by virtue of their inherent targeting capability and folding energy. pHLIPmediated intracellular delivery of PNAs targeting the miR-155 oncomiR was
shown in a mouse model of large B-cell lymphoma [56]. Treatment of
lymphadenopathic miR-155 mice with pHLIP anti-oncomiR PNA leads to tumor
burden reduction and prevention of lymphocyte metastases.
Another approach to gene therapy involves the intracellular delivery of
plasmid DNAs (pDNAs). In one study, a pDNA expressing growth factor-interfering
RNA was attached to a dendrimer via electrostatic interaction, and the dendrimerpDNA complex was conjugated to a pHLIP. The study showed higher cellular uptake
at low pH compared to normal pH and resulted in an 86% inhibition of the targeted
growth factor [64].

Targeting of therapeutic agents to cell surfaces
Another interesting use for pHLIPs is the delivery of therapeutic agents to the
extracellular surfaces of cells, which might selectively activate various signaling
pathways. An example of this principle is shown in the use of tissue factor (TF), a
protein that anchors to the plasma membrane and induces blood coagulation.
However, targeting is crucial for the successful use of tissue factor to accomplish
thrombotic occlusion; otherwise, harmful side effects would be common. The tissue
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factor protein naturally has a transmembrane domain that anchors it to cell surfaces. A
study in which the transmembrane domain of the natural tissue factor was truncated
and replaced with a pHLIP (resulting in tTF-pHLIP) showed targeting of the acidic
tumor vasculature, and the tTF-pHLIP induced local blood coagulation. The
administration of the tTF-pHLIP selectively induced thrombotic occlusion in tumorbearing mice, impairing tumor growth without any obvious side effects [65].

Nanotechnology
In the realm of nanotechnology, pHLIPs might find a variety of uses [66]. In
nanotechnology applications, multiple pHLIPs decorate a single nanoparticle, which
can range in size from a few nanometers to hundreds of nanometers, in contrast to the
single peptide-cargo conjugates described above (Box 2). Nanocarriers decorated with
pHLIPs are biocompatible, can target tumors, and demonstrate enhanced cellular
uptake by cancer cells. Some pHLIP-coated nanoparticles that have been investigated
are lipid, polymer, and metal-based nanomaterials [27, 67, 68].
In pHLIP-coated liposomes, pHLIPs promote lipid exchange and fusion
between the lipid bilayer of the liposome and the cellular membrane [67]. Fusion with
cellular or endosomal membranes allows the direct release of polar payloads into the
cytoplasm, or the transfer of hydrophobic payloads into the membrane lipid bilayer
(Figure 4) [67]. The principle of pHLIP-mediated liposomal fusion was used to
deliver the hydrophobic peptide gramicidin A, a monovalent ion channel. Introducing
pores into the targeted cell membrane disrupts ion balance, resulting in apoptosis [67].
This case demonstrates that pHLIPs might be used not only to improve liposome
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targeting over passive targeting methods, but also to enhance payload delivery into
cells by promoting the fusion of the liposome with the cell membrane.
Gold nanoparticles have found various applications in medicine, including
imaging, radiation therapy enhancement, and hyperthermia localization. The
conjugation of pHLIP to gold nanoparticles has been shown to enhance cancer cell
uptake by over 600% at low pH compared with cells treated with gold nanoparticles
alone [27], and to promote the internalization of gold nanoparticles in human platelets
[69]. Tumor targeting specificity was observed in studies of pHLIP-coated gold
nanoclusters, ultimately resulting in the enhancement of radiation effects and
increased cytotoxicity [70]. Additionally, pHLIP-coated hollow gold nanospheres
(HAuNS) containing chlorin e6 (Ce6), a chemical used to amplify the response of
tumor cells to photodynamic therapy, were developed. The HAuNS-pHLIP-Ce6, when
irradiated with near-infrared light, treated tumors more effectively than hollow gold
nanospheres alone because of the photosensitizer-enhanced hyperthermia due to Ce6
[71, 72].

CONCLUDING REMARKS
pHLIPs have been shown to target cancer tumor acidity. Targeting that
exploits acidity, a physical characteristic ubiquitous to tumors, may have advantages
when compared to other current approaches. Passive targeting, which relies on the
abnormal vasculature present in large tumors, and active targeting, which relies on
specific traits of cancer cells, have disadvantages due to the inconsistent presentation
of passively-targeted traits, the heterogeneity of the cancer cell population, and the
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presentation of targeted traits in healthy cells. These problems can result in failure to
target some cancer cells, the selection of resistant tumor cells, and, ultimately,
ineffective diagnosis, surgery, and therapy due to relapse, the development of
treatment-resistant cancer, and significant damage to healthy tissue.
Not only do pHLIPs target both primary tumor tissue and metastases well, but
the characteristics of the insertion of pHLIPs into cancer cells may make them a useful
tool for many applications (see Outstanding Questions). pHLIPs have been used to
tether imaging agents to cell surfaces for diagnostic imaging and fluorescence guided
surgery. Additionally, the energy of insertion of pHLIPs has been used to deliver
many different types of cargoes into the cytoplasm: small molecules such as toxins,
chemotherapeutic agents, and protein fragments; PNA and pDNA for gene therapy;
and nanomaterials such as liposomes, gold nanoparticles for therapy and imaging, and
drug-laden porous nanoparticles. The pHLIP family of peptides presents novel
opportunities in cancer diagnosis and targeted therapy due to the customizable nature
of the peptides for uses in a wide variety of applications.
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OUTSTANDING QUESTIONS


How can pHLIP® be more effectively used in therapeutic applications? One
of the greatest strengths of pHLIP® is its ability to deliver polar and moderately
hydrophobic cargo molecules across the cellular membrane directly into the
cytoplasm, avoiding the endocytotic pathway and reducing drug resistance.
Optimized pHLIP® drug conjugates could be extremely useful in therapeutic
applications, especially for the treatment of metastatic cancers and cancers which
are difficult to treat, such as triple-negative breast cancers, pancreatic cancer,
infiltrating and diffusive glioblastomas, and potentially many others.



How can pHLIP® and/or the link between peptide and cargo be optimized to
exclusively target cancer cells in order to achieve intracellular delivery of
highly toxic cargoes? Off-target delivery of highly toxic chemotherapeutic agents
(e.g., amanitin) has serious consequences and should be reduced even if the
number of molecules delivered to the target tissue is consequently reduced.
Typically, the delivery of just a few very potent drug molecules is enough to
induce a cytotoxic effect.



How can pHLIP® and/or the link between peptide and cargo be optimized for
the efficient intracellular delivery of large quantities of less toxic cargoes? For
some cargoes, like those which alter gene expression (e.g., PNA), the cargo itself
is very specific to its target within cancer cells, and off-target delivery does not
pose significant problems. At the same time, these types of cargoes need to be
delivered in larger quantities to induce a noticeable biological effect.
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GLOSSARY
Amphipathic pore-forming peptides: Peptides possessing both hydrophobic and
hydrophilic regions that insert and assemble to form pores in the cellular membrane
Cell-penetrating peptide (CPP): A peptide, typically with a strong positive charge,
that binds to the phospholipids of the cell membrane and is taken up by the cell
Drug-like molecule: A molecule that exhibits properties similar to those of
established drugs; for example, per Lipinski’s Rule of Five: no more than five
hydrogen bond donors, no more than ten hydrogen bond acceptors, molecular weight
below 500 Da, and an octanol-water partition coefficient log P ≤ 5
F-actin: Filaments that are part of the cell cytoskeleton and contribute to structural
stability and cell movement
ICG (indocyanine green): An FDA-approved fluorescent dye used to mark blood
vessels in angiography and perfusion diagnostics, but does not target the tumor itself
MicroRNA: Small molecules of RNA that play a functional role in gene expression
by blocking messenger RNA translation
Non-standard amino acids: Amino acids that are not encoded in the human genome
PAR1 (proteinase-activated receptor 1): A member of the large family of G proteincoupled receptors that plays a functional role in the blood coagulation process
Passive diffusion: The ability of molecules to cross cell membranes on their own
Passive targeting methods: Targeting methods that rely on naturally-occurring
biological characteristics, such as non-intact tumor vasculature, to induce the
localization of cargo within a tumor
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Peptide nucleic acid (PNA): Artificial DNA- or RNA-like molecule with a peptide
backbone that forms a sequence-specific base-paired complex with DNA or RNA
pHLIP®: The pH (low) insertion peptide; pHLIP is a registered trademark
Positive margin: The condition that exists after surgical resection when the surgery
was not successful in removing all cancerous tissue
RNA polymerase II: A key enzyme that catalyzes transcription
SNARF (seminaphtharhodafluor): A fluorescent dye with two pH-dependent
emission peaks, making possible the use of SNARF to measure pH through
spectrography or ratiometric imaging
Tissue factor (TF): Protein that is exposed to the blood upon tissue damage,
triggering blood clot formation
Tubulin: A family of proteins that polymerize into microtubules, which are part of the
cytoskeleton and contribute to structural stability, cytoplasmic transport, cell
movement, and cell division
Transmembrane helix: The formation by a polypeptide of a helix that spans the lipid
bilayer of a cellular membrane
Triple-negative breast cancer (TNBC): Any breast cancer that does not express the
estrogen receptor, progesterone receptor, and epidermal growth factor receptor 2
(HER2/neu), making TNBC more difficult to treat due to the reliance of typical
chemotherapies on the expression of one or more of these receptors
Tumor invasion: The spread of cancer cells (metastasis) from the primary tumor site
to adjacent tissue or blood
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FIGURES

Figure 1. pHLIP membrane interaction and insertion. The peptides of the pHLIP
family (blue) exist in equilibrium between solvated and membrane-adsorbed
conformation at the normal extracellular pH found in healthy tissue, whereas peptides
insert across cellular membrane at the low extracellular pH found in acidic, diseased
tissue.
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Figure 2. Mechanism of pHLIP insertion into the cellular membrane. When the
pHLIP (blue) encounters healthy tissue where the extracellular pH is around pH 7.4,
the protonatable residues of the pHLIP (red circles) remain deprotonated and
negatively charged, and the peptide resides at or near the hydrophilic surface of the
cellular membrane. Weakly bound to the membrane, the pHLIP is washed from the
membrane via normal perfusion and continues to circulate through the body. Cancer
cells, however, produce excess acidity as a consequence of their malfunctioning
metabolisms and overexpression of certain surface proteins, and pump these acidic
byproducts out of the cell interior in order to maintain comfortable conditions inside
the cell, resulting in the acidification of tumor tissue. When the pHLIP encounters
tumor tissue, it senses the low extracellular pH at the cancer cell surface (i.e., the
concentration of protons (cyan circles) at the surface of the cellular membrane is
high), and the protonatable residues and negatively charged C-terminal carboxyl group
of the pHLIP become neutrally charged (green circles). The protonation leads to an
increase in the overall hydrophobicity of the pHLIP, increasing the affinity of the
peptide to the hydrophobic core of the cellular membrane and triggering the pHLIP to
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spontaneously fold into a helix and insert across the membrane, resulting in the
formation of a transmembrane helix. When the C-terminal protonatable residue and
carboxyl group are then exposed to the normal intracellular pH of the cell, they are
deprotonated, again becoming negatively charged, and anchor the pHLIP in the
membrane.
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Figure 3. Two uses for pHLIPs: tethering cargo to the cell surface or
translocating cargo across the membrane into the cytoplasm. A pHLIP (blue) can
be used to target and tether cargo molecules to the surfaces of cells in low pH
environments (A). The cargo could be an optical marker, a PET or SPECT imaging
agent, or an antigen or protein delivered to induce certain cellular processes. A pHLIP
can also be used for the intracellular delivery of payloads, translocating cargo (green)
across the membranes of cells with low extracellular pH, such as those cells found in
acidic, diseased tissue (B). These payloads are conjugated to the membrane-inserting
end of the pHLIP, typically via a cleavable link (magenta), and could include toxins,
chemotherapeutic agents, or agents to alter gene expression.
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Figure 4. A postulated pathway for fusion and cellular uptake of pHLIP-coated
liposomes. pHLIP-coated liposomes interact with the membrane and promote either
direct fusion with the lipid bilayer of the membrane (A), or uptake via the endocytotic
pathway (B), followed by fusion with the endosomal membrane. Both uptake
mechanisms result in the cytoplasmic delivery of encapsulated polar cargo (green), or
delivery of lipid membrane-incorporated hydrophobic payloads to the membrane
(red). Schematic is not to scale.
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BOXES
Box 1. Peptides of the pHLIP family share the same features in their primary
sequences (Figure I) and exhibit the same mechanism of action (Figure 2). These
shared characteristics include: i) an N-terminal region (flanking sequence 1) that
varies from 3 to 20 residues and consists mainly of polar amino acids that contribute to
the overall solubility of the peptide and are used for conjugation with cargo destined
for the extracellular space; ii) a middle region (transmembrane sequence) that varies
from 15 to 25 residues and consists mainly of hydrophobic residues, but also includes
amino acids that are negatively charged at physiological pH but become neutrally
charged at low pH due to protonation; and iii) a C-terminal region (flanking sequence
2) that varies from 0 to 10 residues and may contain a few additional protonatable
residues, as well as residues for conjugation with cargo that will be delivered across
the cellular membrane to the cytoplasm. Single cysteine and/or lysine residue can be
used for conjugation with cargo molecules and can be introduced into one or both
flanking sequences.
These features are reflected in the sequences of the wild-type (WT) and the Variant 3
(Var3) pHLIPs, seen below, where protonatable residues are shown in red and the
putative transmembrane region is underlined:
WT:

AEQNPIY WARYADWLFTTPLLLLDLALLVDAD EGT

Var3: ADDQN PWRAYLDLLFPTDTLLLDLLW
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Figure I. The main features of sequences of the pHLIP peptide family. Members
of the peptide of pHLIP family follow a similar pattern in terms of peptide sequence:
an N-terminal flanking region (yellow) consists mainly of polar residues; a
transmembrane region (red) consists mainly of hydrophobic residues, but also includes
protonatable residues which prevent insertion at physiological pH; and a C-terminal
flanking region (green), which may not present in all peptides, contains a few
additional protonatable residues. Cargo can be conjugated either to the C- or Nterminus via single cysteine or lysine residues.
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Box 2. Not only can pHLIP conjugates be constructed in a one-to-one ratio between
pHLIP (blue) and cargo (red), but the pHLIP can also be used to coat molecules in
order to increase biocompatibility, targeting, and to induce cellular uptake (Figure II).
Nanoparticles, for instance, have a wide variety of uses in medical applications,
including as drug-laden nanocarriers, as particles that enhance another form of
therapy, and as therapeutic agents themselves. Decorating nanoparticles with multiple
pHLIPs not only results in targeting specificity and greater uptake by cells in acidic,
diseased environments, but can also bestow biocompatibility on what might be an
otherwise non-biocompatible nanoparticle. pHLIPs could be used as decorations on a
wide variety of nanoparticles, and have already been studied in lipid, polymer, and
metal-based nanomaterials.
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Figure II. pHLIP delivery capability. pHLIPs are used to increase the tumor
targeting and delivery of various types of cargoes, such as imaging agents and
therapeutics, by conjugating cargo to pHLIP in a one-to-one ratio (A). pHLIPs can
also be used to decorate nanoparticles (B), to increase the biocompatibility, tumor
targeting and promote cellular uptake of nanoparticles by cancer cells.
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ABSTRACT
pH (low) insertion peptides (pHLIP peptides) target acidic extracellular environments
in vivo due to pH-dependent cellular membrane insertion. Two variants (Var3 and
Var7) and wild-type (WT) pHLIP peptides have shown promise for in vivo imaging of
breast cancer. Two positron emitting radionuclides (64Cu and 18F) were used to label
the NOTA- and NO2A-derivatized Var3, Var7, and WT peptides for in vivo
biodistribution studies in 4T1 orthotopic tumor-bearing BALB/c mice. All of the
constructs were radiolabeled with 64Cu or [18F]-AlF in good yield. The in vivo
biodistribution of the 12 constructs in 4T1 orthotopic allografted female BALB/c mice
indicated that NO2A-cysVar3, radiolabeled with either 18F (4T1 uptake; 8.9 ±
1.7%ID/g at 4 h p.i.) or 64Cu (4T1 uptake; 8.2 ± 0.9%ID/g at 4 h p.i. and 19.2 ± 1.8%
ID/g at 24 h p.i.), shows the most promise for clinical translation. Additional studies to
investigate other tumor models (melanoma, prostate, and brain tumor models)
indicated the universality of tumor targeting of these tracers. From this study, future
clinical translation will focus on 18F- or 64Cu-labeled NO2A-cysVar3.

40

INTRODUCTION
Cancer cells, in general, prefer the glycolytic pathway of energy production as a
consequence of their deregulated proliferative machinery and requirement for survival,
which results in excess acidity. To maintain homeostasis, cancer cells release lactic
acid, formed during glycolytic processes, to the extracellular environment.(1-3) The
release of acid lowers the extracellular pH immediately surrounding these cells
relative to the pH of normal tissues. Due to the differential in pH gradients, a probe
marking these acidic regions in rapidly proliferating tissues can potentially distinguish
cancerous from normal tissue.

The family of pH (low) insertion peptides (pHLIP peptides) represents a novel class of
delivery agents which can target acidic malignant tissue.(4, 5) The molecular
mechanism of targeting is based on the pH-dependent formation of a transmembrane
α-helix, which is accompanied by the insertion of pHLIP peptides into the cellular
membrane in environments with low extracellular pH (Figure 1).(6) Among
investigated pHLIP variants, three were under consideration for clinical translation:
wild-type (WT), variant 3 (Var3), and variant 7 (Var7).(7)

To date, pHLIP peptides have been conjugated to organic dyes or positron-emitting
radioisotopes for in vitro and in vivo studies.(7-11) Viola-Villegas et al. showed that
DOTA-pHLIP variants were able to target PC3-WT cancer cells in a pH-dependent
manner using 68Ga-DO3A-cysWT and 68Ga-DO3A-cysVar7.(12) Additionally, 64Cu-
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NOTA-Var7 showed in vivo localization that was inversely related to measured
extracellular pH (pHe), but with limited overall tumor uptake (1.36 ± 0.43%ID/g).(12)

The selection of NOTA as the chelator in the present studies opened opportunities to
explore radiolabeling strategies with a variety of positron-emitting radiometals, as well
as with 18F, for positron emission tomography (PET) imaging.(13-16) As the previous
studies with pHLIP-PET radiopharmaceuticals in preclinical models established the
proof-of-principle that the pHLIP platform can indeed selectively target and image
tumor acidosis, our goals have now advanced to performing first-in-human trials. It
was first imperative, however, to optimize the tracer (increasing accumulation in the
tumor with a concomitant clearance from nontarget tissues) by careful selection of the
optimal radioisotope and pHLIP peptide variant combination prior to commencing
clinical studies.

In this current study, we investigated and compared the pharmacokinetic properties of
six pHLIP constructs (NOTA-WT, NOTA-Var3, NOTA-Var7, NO2A-cysWT, NO2AcysVar3, and NO2A-cysVar7) labeled with two different PET isotopes (64Cu and 18F)
using an orthotopic breast cancer model (murine 4T1 mammary adenocarcinoma, a
model of human stage IV breast cancer) through ex vivo biodistribution and in vivo
imaging studies. In addition, the biophysical measurements of the nonradioactive,
metalated peptides were conducted to help explain the variations observed in the
animal studies. From these studies, two lead radiopharmaceuticals (18F-AlF-NO2A-
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cysVar3 and 64Cu-NO2A-cysVar3) were selected and further assessed in melanoma,
prostate, and brain tumor models.

RESULTS
Preparing the Radiotracers
The NOTA (1,4,7-triazacyclononane-N′,N″,N‴-triacetic acid) chelator was conjugated
to the pHLIP variants in two ways (Figure 2). The NOTA-pHLIP compounds contain
NOTA with three carboxylic acid groups conjugated to the N-terminus of the peptide
(Figure 2A). The NO2A-cyspHLIP compounds contain NOTA with two carboxylic
acid groups, where the third group was used to conjugate the chelator to the peptide
through the cysteine side chain (Figure 2B). The Cu2+ and AlF2+ NOTA complexes
have an overall charge of −1 with a neutral charge at the N-terminus of the pHLIP
peptides. All complexes with the NO2A-chelates have an overall neutral charge with
the positive charge preserved at the N-terminus of the pHLIP peptides. The three
peptide sequences are tabulated in Figure 2C.

The 64Cu radiolabeling of each of the conjugates was achieved with >60% (isolated)
yield with >93% purity (Supporting Information); the 18F-AlF radiolabeling of each of
the conjugates was 4–50% (isolated and decay corrected to start of synthesis) yield
with >95% purity (Supporting Information). Table S1 lists the specific activity of
each radiolabeled pHLIP peptide.

In Vivo Studies in 4T1 Tumor Models
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Direct evaluation of all 12 tracers in vivo was carried out in 4T1 orthotopic (surgically
implanted) allografted female BALB/c mice in order to determine which compounds
would be best translated into clinical studies. Figure 3 shows the in vivo PET imaging
slices at the level of the tumor at 4 h p.i. of 11 of the 12 tracers tested and the ex vivo
biodistribution in selected organs at 4 and 24 h p.i. (%ID/g, mean ± S.D.). The
corresponding maximum intensity projections (MIPs) from the PET imaging study
and the PET imaging slices at the level of the tumor with a lower maximum value for
better visualization of the tumor at 4 h p.i. for the 18F-AlF-NO2A-cyspHLIP constructs
are collected in Figure S1. The 4 h ex vivo biodistribution values (%ID/g, mean ±
S.D.) are collected in Tables 1 and 2 for all 12 radiopharmaceuticals, and the complete
biodistribution results for all time points are tabulated in the Supporting
Information (Tables S1–1 through S13–14). Due to the ex vivo biodistribution data
for 64Cu-NOTA-Var7 and the previous results from the imaging study of the other
NOTA-pHLIP constructs, an additional imaging study for 64Cu-NOTA-Var7 was
unjustified. These data clearly indicate that all constructs with the NO2A chelator far
outperform the constructs with the NOTA chelator. It appears that NO2A-cyspHLIP
constructs have a longer blood half-life, which results in higher targeting and longer
retention within the tumor while the radiopharmaceutical clears from nontarget tissues
and the blood.

Biophysical Studies
With 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) liposomes as model
membranes, our comparative biophysical investigation of the pH-dependent
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interaction of NOTA-pHLIP and NO2A-cyspHLIP constructs with the lipid bilayer
indicated that NOTA constructs adopt unfavorable conformations at the membrane
surface at physiological and low pH compared to NO2A constructs. Although
biophysical measurements are typically conducted in solutions without the further
addition of ions, we chose to investigate the performance of these constructs in both
the absence and the presence of physiological levels of free magnesium and calcium
ions. Wild-type constructs appear to be sensitive to the presence of divalent cations,
most likely due to the multiple protonatable aspartic and glutamic acid residues at the
inserting end of the peptide, which tend to form divalent complexes with these ions at
physiological pH. Plots demonstrating the changes in fluorescence spectra of AlFNOTA-Var3, Cu-NOTA-Var3, AlF-NO2A-cysVar3, and Cu-NO2A-cysVar3 upon
interaction with membranes are shown in Figure S2.

Figure 3 shows the biodistribution of 64Cu- and 18F-NO2A constructs in selected
tissues at 4 and 24 h. As previously reported,(17) Var7 constructs exhibit the fastest
blood clearance with the highest signal in the kidneys at 4 h p.i. and kidney clearance
at later time points. Both 18F-AlF-NO2A-cysWT and 64Cu-NO2A-cysWT have
slightly higher liver and spleen uptake compared to the corresponding cysVar3 and
cysVar7 conjugates. All of the NO2A constructs demonstrate a pH-dependent
interaction with the lipid bilayer of the cellular membrane (Figures S3 and S4), but
the NO2A-cysWT constructs exhibit the highest affinity to the lipid membrane at
physiological pH. Additionally, the pK of transition from the membrane-bound state to
the inserted state is higher for NO2A-cysWT constructs compared with NO2A45

cysVar3 and NO2A-cysVar7 constructs. This shift in pK is most likely responsible for
the higher uptake of the NO2A-cysWT constructs by the liver and spleen.

Both 64Cu-NO2A-cysVar3 and 18F-AlF-NO2A-cysVar3 had the highest tumoral
uptake, prolonged retention in the tumor, and minimal accumulation in other organs
based on the ex vivo biodistribution data. Figure 4 shows the pH-dependent insertion
and tabulates the percentage of the NO2A-cysVar3 construct population that is
inserted in the membrane at various pHs. The results indicate that less than 5% of the
lead compounds should be inserted into the membrane at pH 7.4 (physiological pH),
whereas greater than 25% of the NO2A-cysVar3 compounds should be inserted into
the cellular membrane at pH 6.0 (the approximate pH at the surface of cancer cells). In
addition, the membrane insertion of Var3 and Var7 takes place at a rate 2 orders of
magnitude higher than the rate of insertion of WT.(17)

In Vivo Studies in Prostate, Melanoma, and Brain Tumor Models
The two NO2A-cysVar3 compounds that showed superior targeting of the 4T1 tumors
were compared in melanoma and prostate cancer models. Figure 5 shows the in vivo
PET images of the uptake of the two tracers in tumors at 4 and 24 h p.i. The graph
in Figure 6 directly compares the tumoral uptake of the two lead compounds at 4, 6,
and 24 h p.i. for four of the tumor models investigated in this study. Due to the large
variation in tumor size for the LNCaP tumors, the ex vivo data shows a minimal
increase in tumoral uptake over the PC3 tumors, but both the murine B16–F10
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melanoma tumors and 4T1 breast cancer tumors showed greater uptake of the tracers
compared to the human prostate cancer models.

Because of the low uptake of the tracers in brain tissue, the 18F-AlF-NO2A-cysVar3
was also evaluated in U87MG tumor-bearing mice. These tumors were implanted into
the brain cavity or xenografted subcutaneously on the flank of nude mice. Figure
S5 shows the imaging of these tumors. The uptake in the U87MG tumors that were
implanted into the brain cavity showed significant uptake of the tracer in the portion of
the tumor that was outside the skull. During necropsy, these tumors did not show
significant infiltration of the brain. The ex vivo biodistribution of 18F-AlF-NO2AcysVar3 at 6 h p.i. in the nude mice with flank tumors is included in Figure S5. In
order to conclusively determine if the uptake of 18F-AlF-NO2A-cysVar3 was only in
the portion of the tumor outside of the skull, a group of mice with GSC 5–22 tumors
orthotopically xenografted behind an intact blood-brain barrier (BBB) were obtained.
During necropsy, these tumors had infiltrated half of the brain, but there was no
uptake observed in the PET image (Figure S5).

Specific Activity Investigation
The tracers were prepared to have comparable specific activities (approximately 100
μCi/nmol (3.7 MBq/nmol)) for most of the studies. A few additional studies were
conducted with higher and lower specific activities in order to compare the effect of
specific activity on tumoral uptake. The data sets were analyzed individually and
showed that specific activity did not impact the biodistribution of the tracers,
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especially tumoral uptake. Thus, all of the data points for similar tumor models were
averaged in aggregate (regardless of specific activity) and tabulated together in
the Supporting Information.

Tissue Autoradiography
The uptake of 64Cu-NO2A-cysVar3 (24 h p.i.) in LNCaP and PC3 tumors was
investigated via autoradiography with viable tissue stained with hematoxylin and eosin
(H&E) to determine if the uptake was specific to regions showing indications of
metabolic stress or necrosis. Interestingly, uptake of 64Cu-NO2A-cysVar3 appears to
correlate with necrotic regions in LNCaP tumors, but not in PC3 tumors (Figure 7).
This could be a result of the PC3 tumors having less necrosis overall than the LNCaP
tumors in this study. Additionally, the autoradiography shows increased relative
uptake of 64Cu-NO2A-cysVar3 (24 h p.i.) in LNCaP over PC3 tumors (Figure S6).
This finding is similar to the results from previous studies by our group, in which both
LNCaP and PC3 tumors were investigated.(10-12) H&E staining of tumor sections
from 4T1 tumors excised 5–12 days post-inoculation show non-necrotic tumor tissue;
thus, the greater tumoral uptake of the 64Cu-NO2A-cysVar3 (according to the ex vivo
biodistribution data) does not appear to be correlated to necrosis.

DISCUSSION
Two positron-emitting radionuclides (18F and 64Cu) can be used to label NOTApeptides for in vivo imaging. While 64Cu (t1/2 = 12.7 h) has a moderately short half-life,
the production of 64Cu requires a higher energy cyclotron and expensive targetry with
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automated radionuclidic separation which many institutions do not currently have.
Conversely, 18F (t1/2 = 109.8 min) is readily available from most medical cyclotrons
and radiopharmaceutical centers, is routinely produced at numerous sites worldwide,
and can be inexpensively concentrated for radiolabeling. Unlike conventional
nucleophilic 18F labeling of small organic molecules, using a chelator to coordinate the
aluminum center of [18F]-AlF is straightforward and can be done in aqueous
solution.(15, 16)

After the radiopharmaceuticals were successfully synthesized, their ability to target
cancerous tissue was directly compared in 4T1 tumor-bearing female BALB/c mice.
This model of triple-negative human stage IV breast cancer was chosen based on
previous findings in our group that the pHLIP-PET agents were excreted through both
the hepatobiliary and renal pathways and showed very good tumor:muscle ratios.(1012) As such, breast cancer seemed an appropriate target which is imaged in humans
away from these excretion organs. Additionally, previous results from Serganova et al.
indicated that the pH of 4T1 tumors increases with increased size.(18) Thus, the 4T1
tumors in this study were purposely used 5–7 days after inoculation to ensure lower
tumoral pH. The ex vivo biodistribution data show that the metalated NOTA-pHLIP
variants are quickly cleared via both the hepatobiliary and renal pathways to reduce
the overall circulating radioactivity significantly by 12 h p.i. The rapid excretion of
the 64Cu-NOTA-pHLIP variants from the intestines and slow elimination from the
kidneys over time indicate that the compounds are not being taken up by the cells
within these organs, but are being eliminated via these pathways. Additionally, when
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comparing the 2 h ex vivo data for kidneys-to-large intestine ratios [64Cu-NOTA-WT
is 0.35 ± 0.11; 18F-AlF-NOTA-WT is 0.42 ± 0.03; 64Cu-NOTA-var3 is 0.29 ±
0.12; 18F-AlF-NOTA-var3 is 0.52 ± 0.15; 64Cu-NOTA-var7 is 0.32 ± 0.07; 18F-AlFNOTA-var7 is 0.55 ± 0.19], there is no significant difference between the excretion
pathways of variants radiolabeled with 64Cu or 18F. Perhaps the charge of the
complexes appended to the pHLIP peptides helps to improve the elimination of these
compounds, but also decreases the likelihood of uptake in low pH environments, such
as the tumor, which may require more residence time in the blood. The lack of tumor
targeting is evident in the imaging study results shown in Figure 3.

Conversely, the neutrally charged NO2A complexes conjugated to the cysteine residue
of pHLIP peptides (which preserve their positive charge at the N-terminus) show
prolonged blood circulation with slower clearance, consequently leading to better
perfusion of the tracers in the tumor microenvironment where they are effectively
trapped. The steady increase of the tumoral uptake of each of the tracers implies slow
localization in the tumor site. The radiometalated NO2A-cysVar7 compounds had the
shortest blood retention with similar tumoral uptake at 4 h to the other radiolabeled
compounds. This rapid blood clearance may make the radiometalated NO2A-cysVar7
compounds useful for shorter imaging times (tumor is visible in the slices at the tumor
level in Figure S1) as long as the tumor is sufficiently distant from the kidneys (the
major organ visible in the MIP in Figure S1). The rapid clearance of the Var7
constructs (noted in previous studies(17, 19)) may be a function of their physical
characteristics. While these compounds have pKs of insertion similar to the NO2A50

cysVar3 constructs, they are less hydrophobic than the NO2A-cysVar3 constructs.
This lower hydrophobicity results in faster blood clearance (indicated by lower
amounts of NO2A-cysVar7 constructs in the blood at every time point). The lower
amount of radiolabeled compound in the blood for longer periods of time may result in
lower tumoral uptake of the NO2A-cysVar7 constructs because the targeted tissue is
exposed to less of the construct. At the same time, NO2A-cysWT compounds
exhibited highest accumulation in liver and spleen compared to NO2A-cysVar3 and
NO2A-cysVar7, most probably due to their higher membrane affinity (greater
hydrophobicity)

at

physiological

pH

and

slower

rate

of

membrane

insertion.(17) Additionally, the 64Cu-NO2A-cyspHLIP derivatives show decreased
radioactivity accumulation in the kidney from 4 h p.i. to 24 h p.i. which is due to
clearance of the drug rather than uptake, whereas the liver and spleen uptake remains
similar for the two time points. The liver and spleen uptake may be due to loss of
the 64Cu from the chelator,(20) digestion of the radiotracer in vivo, or accumulation of
intact tracer in these organs. Further investigation of this uptake is currently underway
by investigating a pHLIPcys-NO2A derivative that contains the cysteine residue on
the internalized portion of the peptide (C terminus), which could result in lower liver
and spleen uptake if the uptake in these organs is due to loss of the 64Cu from the
chelator after membrane insertion.

From these results it becomes evident that introducing a benzene ring in close
proximity to the N-terminus of the peptide sequence and using a negatively charged
metal complex should be avoided in pHLIP peptide-mediated tumor imaging
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pharmaceuticals. Instead, conjugating to either the cysteine side chain or utilizing a
suitable linking group on the N-terminus may improve tumor targeting of the
synthesized pHLIP peptide. These general guidelines may help explain the
improvements seen in this study and understand the results from previous studies.

Two compounds from the 12 tracers included in this study showed the greatest
tumoral uptake and significant tumor-to-background contrast in the images throughout
the imaging studies: 64Cu-NO2A-cysVar3 and 18F-AlF-NO2A-cysVar3. Therefore, we
next investigated the in vivo properties of these two tracers in PC3 and LNCaP tumorbearing mice to compare tumoral uptake with previous studies.(10-12) In these tumor
models, the tumor accumulation of 64Cu-NO2A-cysVar3 and 18F-AlF-NO2A-cysVar3
was significantly higher compared to previous generations of PET isotope-labeled
pHLIP constructs, especially at 24 h p.i. (Figure S7). Of particular note is the uptake
of the 18F-py-click-6Ahx-WT reported by Daumar et al.(11) and 68Ga-DO3A-cysVar7
reported by Viola-Villegas et al.(12) Both of these previously reported compounds
show significant uptake at 4 h p.i. and could be clinically useful. By comparison of the
tumor:tissue ratios with those of previously reported compounds (Figure S8), the
tumor:muscle ratios at 4 h p.i. were 7.4 ± 1.3 (64Cu-NO2A-cysVar3), 6.9 ± 1.9 (18FAlF-NO2A-cysVar3), 4 ± 2 (18F-py-click-6Ahx-WT), and 1.1 ± 1.5 (68Ga-DO3AcysVar7) in PC3 tumor-bearing male nude mice; the tumor:bone ratios were 2.7 ± 0.6
(64Cu-NO2A-cysVar3), 3.2 ± 0.7 (18F-AlF-NO2A-cysVar3), 1.3 ± 0.4 (18F-py-click6Ahx-WT), and 0.4 ± 0.3 (68Ga-DO3A-cysVar7) in PC3 tumor-bearing male nude
mice. Additionally, the tumor:muscle ratios in LNCaP tumor-bearing male nude mice
52

at 4 h p.i. were 6 ± 2 (64Cu-NO2A-cysVar3), 4.7 ± 0.9 (18F-AlF-NO2A-cysVar3), and
6 ± 3 (18F-py-click-6Ahx-WT); the tumor:bone ratios in LNCaP tumor-bearing male
nude mice at 4 h p.i. were 4.2 ± 1.7 (64Cu-NO2A-cysVar3), 4.3 ± 1.1 (18F-AlF-NO2AcysVar3), and 1.8 ± 0.6 (18F-py-click-6Ahx-WT). In each of these cases, the tumor
ratios of the two lead compounds from this study are much better than the 68GaDO3A-cysVar7, which would result in improved image contrast. While the 18F-pyclick-6Ahx-WT had similar tumor:muscle ratios, the tumor:bone ratios were much
lower than the two lead compounds in both prostate cancer tumor models. The
decreased tumor:bone ratios may indicate that the previously reported 18F-py-click6Ahx-WT was more prone to defluorination than the 18F-labeled tracers presented in
this study.

Despite the similar tumor-targeting properties, the preparation of 18F-py-click-6AhxWT requires two HPLC-based separations and generates a volatile radioactive
intermediate. The preparation of either of the lead compounds from this work, in
contrast, did not required HPLC purification or heating beyond 80 °C which is optimal
for rapid dose-on-demand production of the tracers for patient trials. Thus, the two
lead compounds from this study appear to be the best candidates for clinical
translation because of their improved biopharmaceutical properties and facile
radiosynthesis.

Two other tumor types (melanoma and glioma) were included in this study to
determine if the high uptake of these radiotracers seen in breast and prostate cancer
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models would translate to other types of tumors. The lead compounds have excellent
tumor:background contrast in B16–F10 murine melanoma tumor-bearing mice, which
was useful to identify very small tumors (<17 mg; ∼4 mm3) in the PET image.
Because of the contrast and high uptake, we plan to continue investigating the use of
the two lead compounds in metastatic B16–F10 tumor models. For the brain tumor
models, both an orthotopic and a subcutaneous (flank) brain tumor mouse model
indicated that the 18F-AlF-NO2A-cysVar3 was unable to penetrate an intact BBB, but
was able to target brain tumors that had developed outside the BBB (Figure S5).
Because this is a peptide-based tracer, we did not expect the compound to be able to
cross an intact BBB; thus, these tracers may be useful in identifying metastases and
possibly brain tumors in situations of compromised BBBs.

Previously, autoradiography was performed by Viola-Villegas et al. in prostate tumor
sections from excised PC3 and LNCaP tumors in order to show differences in
histology and tracer uptake;(12) thus, a similar study was performed with the uptake
of 64Cu-NO2A-cysVar3 in the same tumor lines. Overall, the ex vivo tumor sections
show increased uptake of the 64Cu-NO2A-cysVar3 in the necrotic regions of the
LNCaP tumors (Figure 7). This may indicate that if necrosis is present, then uptake
of 64Cu-NO2A-cysVar3 may increase, but is not the only requirement. The findings
here generally match the trend found by Viola-Villegas et al. in prostate tumor
sections.(12) Additionally, the greater uptake in the allografted tumors may indicate
the relative overall tumor environment is less acidic (higher) in the slower growing
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human cell lines investigated (PC3 and LNCaP), but is more acidic (lower) in the
faster growing murine cell lines (B16–F10 and 4T1).

EXPERIMENTAL SECTION
The D-amino acid versions of NOTA-derivatized pHLIP peptides were purchased
from CS Bio (Menlo Park, CA) with ≥95% purity (combination of both chelators and
three variants from Figure 2: NOTA-WT, NOTA-Var3, NOTA-Var7, NO2A-cysWT,
NO2A-cysVar3, and NO2A-cysVar7). All other chemicals were purchased from
commercial suppliers without further purification unless otherwise stated. Detailed
method descriptions are found in the Supporting Information.

Radiochemistry
General Labeling Methods for 64Cu-NOTA-pHLIP
Following a preparation similar to that of Zeglis et al.,(21) 64Cu was diluted in a 100
mM NH4OAc buffer (pH ∼ 5.5) and reacted with a NOTA-pHLIP derivative at 80 °C
for 15 min.

General Labeling Methods for 18F-AlF-NOTA-pHLIP
Following a modified labeling method described by Dijkgraaf et al.,(22) 18F from the
cyclotron target water was concentrated using a chromafix cartridge into 0.1 mL of 0.4
M KHCO3 in metal-free water. The pH was adjusted and 0.1 mL AcN added. To this
solution, AlCl3 (80 nmol) in 0.1 M NH4OAc buffer (pH ∼ 4.1) was added. After 5
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min, the NOTA-pHLIP derivative was added and the reaction mixture reacted at 75 °C
for 15 min.

General Purification
An Oasis HLB Plus Light or C18 Sep-Pak Light cartridge (Waters, Milford, MA) was
used to remove unbound activity. The pure radiolabeled NOTA-pHLIP derivatives
were eluted with EtOH and diluted with sterile phosphate buffered saline (PBS) with
radiochemical purities >93% before administration to animals.

Animal Models
Animal studies were conducted according to an MSKCC IACUC-approved animal
protocol. 4T1 (orthotopic breast cancer allografts of 1 × 106 cells surgically implanted
in the mammary fat pad) and B16–F10 (orthotopic melanoma allografts of 1 ×
105 cells injected intradermally on the shoulder) tumors were orthotopically
inoculated in media in female BALB/c and C57Bl/6 mice (Charles River Laboratories
(CRL)), respectively. Additionally, PC3 (3 × 106 cells) or LNCaP ((3–6) × 106 cells)
tumors were subcutaneously xenografted on the shoulder of athymic nude male mice
(CRL). Mice were used once tumor volumes were approximately 90–300 mm3.

In Vivo Animal PET Imaging and Biodistribution
Mice were injected with radiolabeled NOTA-pHLIP derivatives i.v. (500–700
μCi/mouse for PET imaging studies and 25–100 μCi/mouse for biodistribution
studies). All injections were less than 200 μL with <10% EtOH in sterile PBS. PET
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images were obtained with the mice under anesthesia in an Inveon PET-CT or
microPET Focus 120 (Siemens) at 0.5–48 h p.i. All images were analyzed using
ASIPro VM (Concorde Microsystems). Dissections for ex vivo biodistribution were
performed on mice after CO2 asphyxiation or cervical dislocation while anesthetized
at reported time points. Weight of the syringe prior to injection and after injection was
used to determine the mass of injectate. Activity of the syringe prior to injection and
after injection was used to determine the percent of injectate administered. The mass
injected was corrected by the percent of radioactivity injected. Four to five aliquots
(10 μL) were weighed and counted as internal standards for each study. All of the
collected organs were counted using an automatic gamma counter (Wizard 3″,
PerkinElmer, Waltham, MA). The total injected dose was found as the mass injected
dose × fraction radioactivity injected × internal standard average counts/g. The percent
injected dose (%ID) was determined as the counts for the tissue × 100/total injected
dose. The %ID/g was calculated as the %ID/tissue weight. The average and standard
deviation of the %ID and %ID/g was determined using normal methods (n – 1) for
each set of mice.

Ex Vivo Autoradiography, Staining, and Microscopy
Tumors were excised from the mouse, embedded into Tissue-Plus O.C.T. (Scigen,
Gardena, CA), stored at −20 °C until sectioning, and cut in sequential 10 μm sections.
Select sections were exposed to autoradiography film (Fujifilm, GE Healthcare) for 1–
3 days and read using a typhoon photographic film scanner (GE Healthcare).
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Additionally, sections were stained with H&E for gross tumor microscopy and then
scanned.

Biophysical Studies
Biophysical studies were conducted on nonradioactive standards of the NOTA-pHLIP
and NO2A-cyspHLIP compounds. All experiments were conducted with a 5 μM to 1
mM construct to lipid ratio. State I (construct with no liposomes in solution) and State
II (construct in the presence of liposomes) were measured at pH 8; for State III
(construct in the presence of liposomes), the pH of solution was dropped to pH 4 using
2 M HCl. Experiments were conducted in 10 mM phosphate buffer (Sigma-Aldrich)
either without additional ions or in the presence of physiological levels of free
magnesium and calcium (0.65 mM and 1.25 mM, respectively).

Liposome Preparation
Large unilamellar vesicles were prepared by extrusion. 1-Palmitoyl-2-oleoyl-snglycero-3-phosphocholine (POPC; Avanti Polar Lipids) was dissolved in chloroform
at a concentration of 12.5 mg/mL, desolvated by rotary evaporation, and dried under
high vacuum for 2 h. The phospholipid film was then rehydrated in 10 mM phosphate
buffer (pH 8.0 with or without ions), vortexed, and extruded 15× through a 50 nm
pore.

Steady-State Fluorescence
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Tryptophan fluorescence spectra were measured using a PC1 ISS spectrofluorometer
(Champaign, IL) with temperature control set to 25 °C. Fluorescence spectra were
recorded with excitation and emission slits set to 1 mm, using an excitation
wavelength of 295 nm, with excitation and emission polarizers set to 54.7° and 0°,
respectively.

Steady-State Circular Dichroism
Circular dichroism measurements were taken using a MOS-450 spectrometer (BioLogic SAS, Claix, France) with temperature control set to 25 °C in the range of 190 to
260 nm with step of 1.0 nm.

pH Dependence
The pH-dependent insertion of the construct population was investigated using the
shift in position of the wavelength of maximum intensity of the tryptophan
fluorescence spectra varying pH conditions between 4 and 8. The pH after addition of
HCl was measured using an Orion PerpHecT ROSS Combination pH Micro Electrode
and an Orion Dual Star pH and ISE Benchtop Meter (Thermo Fisher Scientific).
Tryptophan fluorescence spectra were recorded at each pH value and were analyzed
using an online protein fluorescence and structural toolkit (PFAST) to obtain the
positions of spectral maxima (λmax). Finally, the positions of λmax were plotted as a
function of the various pHs and the Henderson–Hasselbalch equation employed to fit
the data

, where λmax1 and λmax2 are the positions of spectral

59

maxima at the end and beginning of the State II – State III transition, respectively, n is
the cooperativity parameter, and pK is the midpoint of transition.

CONCLUSIONS
In our study, the NO2A-cysVar3 is the lead construct for clinical investigation. This
construct can be radiolabeled with 18F or 64Cu with similar pharmacokinetic
properties. The availability, limited dose exposure due to its short half-life, and cost
effectiveness of 18F supports the utility of 18F-AlF-NO2A-cysVar3 in the clinic.
Nevertheless, 64Cu-NO2A-cysVar3 may be more suitable for inpatient imaging (where
the patient will be in the clinic longer than 24 h) and in centers where the availability
of the PET scanner may impact the time when patients are imaged. Clinical evaluation
of these radiopharmaceuticals is currently underway.
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ABBREVIATIONS
AcN

acetonitrile

H&E

hematoxylin and eosin

MIP

maximum intensity projection

NOTA

1,4,7-triazacyclononane-N′,N″,N‴-triacetic acid

pHLIP

pH (low) insertion peptide

pHLIP-PET

pHLIP radiolabeled with a positron emitting nuclide
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FIGURES

Figure 1. Three folding states of pHLIP peptides in decreasing extracellular pH:
unfolded and unbound peptide in solution (State I), unfolded peptide loosely
interacting with the membrane lipid bilayer at physiological pH (State II), and folded
peptide in α-helical conformation inserted across the membrane at low extracellular
pH (State III).
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Figure 2. Two chelators [(A) NOTA-pHLIP and (B) NO2A-cyspHLIP] and (C) the
peptide sequences used in this study. The chiral centers within the chelator and linker
are marked with asterisks.
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Figure 3. Coronal PET image slices at the level of the tumor at 4 h p.i. (A) and ex
vivo biodistributions in selected organs at 4 h (B) and 24 h p.i. (C) showing
differences in the tracer distribution in BALB/c female mice bearing 4T1 tumor
allografts. The yellow arrowheads in (A) indicate where the tumor is located in the
mouse. The selected scale on the PET images does not allow for tumor visualization in
the case of the NO2A-cysVar7 constructs. Figure S2 shows the maximum intensity
projections (MIPs) for these compounds at 4 h and the slices at the level of the tumor
for the 18F-AlF-NO2A-cyspHLIP constructs with a maximum value of 15%ID/g. Only
ex vivo biodistribution data was obtained for 64Cu-NOTA-Var7.

68

Figure 4. pH dependent bilayer insertion of NO2A-cysVar3 constructs. Changes in
intrinsic construct fluorescence are used to measure the insertion of the construct
population as a function of pH (transition from State II, at high pH, to State III, at low
pH). Amount of construct population in State II is measured on the y-axis. 95%
confidence intervals are indicated by yellow bands (A). pH-dependence parameters are
used to calculate the percent of inserted construct population at various pH levels (B).
These transitions were measured in the presence of physiological levels of free
magnesium and calcium ions (0.65 mM and 1.25 mM, respectively).
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Figure 5. Slices and maximum intensity projections (MIP) from PET images showing
differences in the radiolabeled NO2A-cysVar3 distribution at 4 and 24 h in BALB/c
female mice bearing orthotopic 4T1 tumor allografts, nude male mice bearing
shoulder PC3 or LNCaP xenografts, and C57Bl/6 female mice bearing orthotopic
B16–F10 tumor allografts. The yellow arrowheads indicate where the tumor is located
in the mouse.
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Figure 6. Graph of the ex vivo tumor uptake of the lead radiolabeled NO2A-cysVar3
in various tumor models at 4, 6, and 24 h p.i.
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Figure 7. Comparison of uptake in sections of excised tumors from PC3 or LNCaP
tumor-bearing male nude mice. The top panels are expansions of the whole tumor
sections shown below. The left-most panels are H&E stained, the middle panels are
the autoradiography, and the right-most panels are overlays.
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TABLES

Table 1. Biodistribution (%ID/g) of the Six Radiolabeled N-Terminus Derivatized
NOTA-pHLIP Derivatives in 4T1 Allografted Female BALB/c Mice at 4 h p.i.
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Table 2. Biodistribution (%ID/g) of the Six Radiolabeled Cysteine Derivatized
NO2A-cyspHLIP Derivatives in 4T1 Allografted Female BALB/c Mice at 4 h p.i.
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SUPPORTING INFORMATION
METHODS & MATERIALS
Radiolabeling
Labeling methods for 64Cu-NOTA-pHLIP. Following a preparation similar to Zeglis et
al.,1 3.13-11.26 mCi (116 – 417 MBq) of

64

Cu in 0.1 M HCl (2.5-6.0 μL, 1.86×104-

1.25×104 mCi/μmol, Washington University, St. Louis, MO) was added to 150 μL of
100 mM NH4OAc buffer (pH ~5.5). An aliquot (25-37 μL) of NOTA-pHLIP
derivative (0.46-0.63 mM) in DMSO was added to the pH adjusted 64Cu solution. The
solution was placed on a thermomixer (Eppendorf, Hamberg, Germany) at 80 °C for
15 min at 1100 rpm. An aliquot of the crude product mixture was HPLC-analyzed (595 % acetonitrile in water (with 0.1 % trifluoroacetic acid) over 15 min, Jupiter C-18
column, Phenomenex, 250 mm × 4.6 mm, 5 μm, 300 Å) to ensure that product was
present (64Cu-NOTA-pHLIP eluted at 10.3 min; 64Cu-NO2A-cyspHLIP eluted at 13.1
min). The remainder of the reaction mixture was separated using a pretreated Oasis
HLB Plus Light or C18 Sep-Pak Light cartridge (Waters, Milford, MA). Free and
unbound

64

Cu was removed by washing the cartridge with 5 mL of water. The pure

64

Cu-labeled NOTA-pHLIP derivatives were then eluted with 1 mL ethanol in 0.1 mL

fractions. The ethanolic fractions with the highest activities were combined and
diluted with sterile phosphate buffered saline (PBS) to provide < 10 % ethanol in the
solution before HPLC analysis (Jupiter C-18, 5 μm, 300 Å, 250 × 4.6 mm,
Phenomenex; 5-95 % AcN in water with 0.1 % TFA over 15 min at 1 mL/min) to
ensure that no free

64

Cu was present. The radiochemical purity of the species was

always > 93 % and the specific activity (using the original amount of peptide added to
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the reaction mixture) was estimated to be 56.0-318.4 μCi/nmol (3.05-11.8 GBq/μmol).
The reaction yielded 1.29-9.54 mCi (47.7-353 MBq) of product with an isolated yield
of 40.7-84.7 %.
Labeling methods for

18

F-AlF-NOTA-pHLIP. Following a modified labeling method

described by Dijkgraaf et al.,2 52.0-60.8 mCi (1.92-2.25 GBq) of
(produced from

18

18

F target water

O enriched target water using a GEMS PETtrace-800 cyclotron,

Memorial Sloan Kettering Cancer Center, New York, NY) was obtained. The target
water was loaded onto a preconditioned chromafix cartridge (30-PS-HCO3, Advanced
Biochemical Compounds (ABX), Germany). [All of the preconditioning solvents and
the elution solution were prepared with metal-free water and trace-metal free
reagents.] The 18F was eluted from the cartridge with approximately 100 μL of 0.4 M
KHCO3 in metal-free water into a 1.5 mL tube (ThermoFisher Scientific, Waltham,
MA). The pH was adjusted to ~4.1 with metal-free acetic acid (Sigma Aldrich). To the
pH adjusted solution, 100 μL of acetonitrile was added. If the total activity exceeded
50 mCi (1.85 GBq), the mixture was split between multiple 1.5 mL tubes prior to
continuing (~10 mCi/40 nmol reaction). To the aliquotted mixture, 20 μL (40 nmol) of
2 mM AlCl3 in 0.1 M NH4OAc buffer (pH ~4.1) was added to each tube. The solution
was allowed to react for 5 min at room temperature before 14-17 μL of 4-5 mM
NOTA-peptide in DMSO (68-75 nmol) was added, the tube capped, and the reaction
mixture reacted at 75 °C for 15 minutes in a thermomixer. After reaction, the mixture
was diluted with 2 mL of metal-free water. An aliquot of the reaction mixture was
HPLC-analyzed (20-95 % acetonitrile in water (with 0.1 % trifluoroacetic acid) over
15 min with an Atlantis T3, Waters, 250 mm × 4.6 mm, 5 μm; Jupiter, Phenomenex,
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250 mm x 4.6 mm, 5 μm, 300 Å, column) to ensure that product was formed (18F-AlFNOTA-WT eluted between 10.1 and 12.1 min;
10.2 and 11.4 min;

18

18

F-AlF-NOTA-var3 eluted between

F-AlF-NOTA-var7 eluted between 8.2 and 10.3 min;

NOTA-cysWT eluted between 13 and 16 min;
between 12 and 15 min;

18

18

18

F-AlF-

F-AlF-NOTA-cysVar3 eluted

F-AlF-NOTA-cysVar7 eluted between 12 and 14 min).

While the HPLC analysis was being performed, the remainder of the reaction mixture
was separated using a pretreated Oasis HLB Plus Light or C18 Sep-Pak Light
cartridge (Waters, Milford, MA) eluting first with water (5 mL) to remove any
unbound

18

mL). The

F species and then ethanol (0.1 mL fractions for 4 fractions and then 0.6

18

F-AlF-NOTA-pHLIP derivatives eluted within the first three fractions in

ethanol. The ethanolic solution was diluted with sterile PBS to provide < 10 % ethanol
in the solution before HPLC analysis (Jupiter C-18, 5 μm, 300 Å, 250 × 4.6 mm,
Phenomenex; 5-95 % AcN in water with 0.1 % TFA over 15 min at 1 mL/min). The
radiochemical purity of the species was always ≥ 95% and the specific activity (using
the original amount of peptide added to the reaction mixture) was estimated to be
79.9-178.1 μCi/μmol (2.96-6.60 GBq/μmol). The reaction yielded 6.02-9.24 mCi
(223-342 MBq) with an overall, decay-corrected (to beginning of labeling procedure)
isolated yield of 2.33-48.6 %.

Nonradioactive standards
General labeling methods for Cu-NOTA-pHLIP. Approximately 200 μL of 36.4 M
Cu(OAc)2 in 0.1 M NH4OAc (pH ~5) in metal-free water was added to 5-6 mg of
peptide in approximately 200 μL of DMSO. The mixtures were reacted in a
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thermomixer at 50 °C for 1 h, and then filtered through a 0.2 μm filter. The filter was
washed with an additional 1 mL of 50% AcN in water and 2 mL of water,
sequentially. The combined filtrate was HPLC purified (10-95% AcN in water over 30
min with a Jupiter C-18 column, 5 μm, 300 Å, 250 × 4.6 mm, Phenomenex). The
collected fraction (14.5-15.5 min for Cu-NOTA-WT, 13.9-15 min for Cu-NOTAVar3, 13.2-14.1 min for Cu-NOTA-Var7, 12.2-13.5 min for Cu-NO2A-cysWT, 1315.3 min for Cu-NO2A-cysVar3, and 12.5-16 min Cu-NO2A-cysVar7) was
lyophilized.
General labeling methods for AlF-NOTA-pHLIP. Sodium fluoride (19.8 mg, 0.47
mmol) was dissolved in 150 μL of 0.1 M NH4OAc in metal-free water (pH ~ 4.1). The
resulting solution was added to 13.7 mg AlCl3 (0.057 mmol) with 50 μL of 0.1 M
NH4OAc buffer (pH ~ 4.1). The AlF3 solution (60 μL) was added to approximately 7
mg of peptide dissolved in 60 μL of EtOH. The reaction mixtures were reacted at 50
°C on a thermomixer for 1 h before being HPLC purified (10-95% AcN in water over
30 min with a Jupiter column, 5 μm, 300 Å, 250 × 4.6 mm, Phenomenex). The
collected fraction (14.7-16.5 min for AlF-NOTA-WT, 13.8-15.4 min for AlF-NOTAVar3, 13-14.6 min for AlF-NOTA-Var7, 12.5-17.5 min for AlF-NO2A-cysWT and
AlF-NO2A-cysVar3, and 12-16 min AlF-NO2A-cysVar7) was lyophilized.

Cell culture methods and in vivo models
4T1 cell culture. The 4T1 cells, derived from spontaneous breast tumor in a BALB/c
mouse, were provided by Fred Miller (Karmanos Cancer Institute, Detroit, MI) and
cultured in Dulbecco’s modified Eagle’s high glucose media with 10 % FCS, 2 mM L-
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glutamine, penicillin, and streptomycin or from ATCC (Manassas, VA) and cultured
in RPMI-1640 medium modified to contain 2 mM L-glutamine, 10 mM HEPES, 1
mM sodium pyruvate, 4.5 g/L glucose, 1.5 g/L NaHCO3, penicillin, and
streptomycin.
4T1 orthotopic BALB/c mouse model. The cells were removed from the flasks,
concentrated, and resuspended in minimal media for cell counting. The cells were then
diluted to contain approximately 1 million cells in 30 μL of media (for orthotopic
allografts). Following an MSKCC Institutional Animal Care and Use Committee
approved protocol, 8-10-week-old BALB/c mice (Charles River Laboratories,
Wilmington, MA) were surgically implanted with one million 4T1 cancer cells into
the first or the last mammary fat pad of the right side of the animal using aseptic
surgical techniques and sterile staple closures while the mice were under anesthetic.
Additionally, mice were given injections of meloxicam (24 h pain killer) in the scruff
and bupivacaine intradermally prior to surgical incisions. One day post-surgery, the
mice were again given meloxicam and checked to ensure that the closure was healing.
Two and three days post-surgery, the mice were checked to ensure that the animals
were healthy and recovering well from the surgery. Five to seven days post-surgery,
the staples were removed. Five to nine days post-surgery, the mice were injected with
50-75 μCi (0.9-0.4 nmol) of the respective radiopharmaceutical for in vivo
biodistribution or 500-600 μCi (9-11 nmol) for in vivo imaging. The mice receiving
64

Cu-NOTA-pHLIP were sacrificed at 1, 2, 4, 12, 24, 36, and 48 h; the mice receiving

18

F-AlF-NOTA-pHLIP were sacrificed at 0.5, 1, 2, 4, 6 and 8 h.
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PC3 cell culture. The PC3 cells, prostate cancer derived from a human bone
metastasis, were purchased from ATCC (Manassas, VA) and cultured in F-12K
Medium (Kaighn's Modification of Ham's F-12 Medium) with, 10% FCS, 2 mM Lglutamine, 1.5 g/L NaHCO3, penicillin, and streptomycin.
PC3 shoulder nude mouse xenografts. The cells were removed from the flasks,
concentrated, and resuspended in minimal media for cell counting. The cells were then
diluted to contain approximately 3 million cells in 150 μL of 1:1 media and matrigel
(for shoulder xenografts). Following an MSKCC Institutional Animal Care and Use
Committee approved protocol, 150 μL of the cell suspension was injected
subcutaneously in 6-9-week-old nude male mice (CRL). Mice were used in studies at
3 weeks post inoculation. The mice were injected with 50-75 μCi (0.9-0.4 nmol) of the
respective radiopharmaceutical for in vivo biodistribution or 500-600 μCi (9-11 nmol)
for in vivo imaging. The mice receiving 64Cu-NOTA-cysVar3 were sacrificed at 1, 4,
12, 24, and 48 h; the mice receiving 18F-AlF-NOTA-cysVar3 were sacrificed at 1, 4, 6
and 8 h.
LNCaP cell culture. The LNCaP cells, prostate cancer derived from a human
supraclavicular lymph node metastasis, were purchased from ATCC (Manassas, VA)
and cultured in RPMI-1640 medium modified to contain 2 mM L-glutamine, 10 mM
HEPES, 1 mM sodium pyruvate, 4.5 g/L glucose, and 1.5 g/L NaHCO3, penicillin, and
streptomycin.
LNCaP shoulder nude mouse xenografts. The cells were removed from the flasks,
concentrated, and resuspended in minimal media for cell counting. The cells were then
diluted to contain approximately 3-6 million cells in 150 μL of 1:1 media and matrigel
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(or shoulder xenografts). Following an MSKCC Institutional Animal Care and Use
Committee approved protocol, 150 μL of the cell suspension was injected
subcutaneously in 6-8-week-old nude male mice (CRL). Mice were used in studies at
3-8 weeks post inoculation. The mice were injected with 50-75 μCi (0.9-0.4 nmol) of
the respective radiopharmaceutical for in vivo biodistribution or 500-600 μCi (9-11
nmol) for in vivo imaging. The mice receiving 64Cu-NOTA-cysVar3 were sacrificed at
1, 4, 12, 24, and 48 h; the mice receiving 18F-AlF-NOTA-cysVar3 were sacrificed at 1,
4, 6 and 8 h.
B16-F10 cell culture. The B16-F10 cells, derived from spontaneous melanoma in a
C57Bl/6 mouse, were purchased from ATCC (Manassas, VA) and cultured in
Dubelco’s modified Eagle’s high glucose media with 10 % FCS, 4 mM L-glutamine, 1
mM sodium pyruvate, 1.5 g/L NaHCO3, penicillin, and streptomycin.
Orthotopic B16-F10 shoulder allografts. The cells were removed from the flasks,
concentrated, and resuspended in minimal media for cell counting. The cells were then
diluted to contain approximately 100,000 cells in 100 μL of media (for shoulder
allografts). Following an MSKCC Institutional Animal Care and Use Committee
approved protocol, C57Bl/6 female mice (CRL) and BALB/c female mice (CRL) were
injected with 100 μL of the cell suspension intradermally as per a media substituted
protocol from Overwijk & Restifo (Current Protocols in Immunology, 2000: 20.1.120.1.29). The mice were used in studies at approximately 9-14 days post inoculation.
The mice were injected with 50-75 μCi (0.9-0.4 nmol) of the respective
radiopharmaceutical for in vivo biodistribution or 500-600 μCi (9-11 nmol) for in vivo
imaging. The mice receiving

64

Cu-NOTA-cysVar3 were sacrificed at 1, 4, 12, 14.5,
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and 24 h; the mice receiving 18F-AlF-NOTA-cysVar3 were sacrificed at 1, 4, 6 and 8
h.
U-87 MG cell culture. The human glioblastoma cell line, U-87 MG, was purchased
from American Type Culture Collection (ATCC, Manassas, VA) and cultured in
Dulbecco’s Modified Eagle’s Medium with 10% fetal bovine serum, 2mM LGlutamine, 1500mg/L Sodium Bicarbonate, 100 units/mL penicillin G and 100 μg/mL
streptomycin (prepared by the MSKCC Media Preparation Core).
U-87 MG shoulder xenografts. The cells were removed from the flasks, concentrated,
and resuspended in minimal media for cell counting. The cells were then diluted to
contain approximately 1 million cells in 150 μL of 1:1 media and matrigel (or
shoulder xenografts). Following an MSKCC Institutional Animal Care and Use
Committee approved protocol, 150 μL of the cell suspension was injected
subcutaneously in 12-week-old nude male mice (CRL). Mice were used in studies at
2-3 weeks post inoculation. The mice were injected with 400-500 μCi (7-10 nmol) for
in vivo imaging. The mice were sacrificed at 6 h after imaging (n=6).
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SUPPORTING INFORMATION FIGURES

Figure S1. PET Maximum intensity projection (MIP) showing differences in the
tracer distribution at 4 h p.i. for all 12 tracers (A) and the PET imaging slices at 15
%ID/g at 4 h p.i. for the

18

F-AlF-cyspHLIP constructs (V) in BALB/c female mice

bearing 4T1 tumor allografts. The yellow arrowheads indicate where the tumor is
located in the mouse. The MIPs correspond to the same images shown in Figure 3.
The slices are the same as those shown in Figure 3, just at 15 %ID/g. Only ex vivo
biodistribution data was obtained for 64Cu-NOTA-Var7.
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Figure S2. Three states of NO2A-cysVar3 and NOTA-Var3 constructs. The
constructs were examined under varying conditions for the presence of the three states
of pHLIP® peptide: State I is the construct in solution at pH 8 (black lines), State II is
the construct in the presence of POPC liposomes at pH 8 (blue lines), and State III is
the construct folded and inserted in the lipid membrane when the pH is dropped from
pH 8 to pH 4 by the addition of an aliquot of HCl (red lines). The concentrations of
construct and lipids were 5 μM and 1 mM, respectively.
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Figure S3. State II and State III of NO2A-cyspHLIP constructs. The constructs were
examined in the presence of liposomes under varying pH levels: State II is the
construct in the presence of POPC liposomes at pH 8 (blue lines), State III is the
construct folded and inserted in the lipid membrane when the pH is dropped from pH
8 to pH 4 by the addition of an aliquot of HCl (red lines). The concentrations of
construct and lipids were 5 μM and 1 mM, respectively, with physiological levels of
free magnesium and calcium ions (0.65 mM and 1.25 mM, respectively).
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Figure S4. pH dependent bilayer insertion of constructs. Changes in intrinsic construct
fluorescence are used to measure the insertion of the construct population as a function
of pH (transition from State II, at high pH, to State III, at low pH). Amount of
construct population in State II is measured on the y-axis. The red and blue lines are
fitting curves and 95% confidence intervals, respectively. These experiments were
carried out with physiological levels of free magnesium and calcium ions (0.65 mM
and 1.25 mM, respectively).
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Figure S5. Initial results from brain tumor uptake study. Images of the uptake of
U87MG tumors xenografted in the skull (U87MG*) or flank (U87MG) on male nude
mice and GSC 5-22 tumors orthotopically xenografted behind an intact BBB in IRCSCID male mice at 4 h post injection (A). The U87MG* tumors did not infiltrate the
brain and only the portion of the tumor that was in the skull bone and protruding from
the skull showed uptake. The construct biodistribution of six male nude mice with
flank U87MG xenografted tumors (B). The yellow arrowheads in (A) indicate where
the tumor is located in the mouse.
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Figure S6. Relative autoradiography of tumor slices from text Figure 6. The slices
show the overall difference in uptake of the tracer at 24 h p.i. Both of the slices were
on the same autoradiography plate and, therefore, are relative to each other.
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Figure S7. Comparison of tumor uptake to previously reported studies for A) PC3 and
B) LNCaP tumor bearing nude male mice at 1, 4, and 24 h with ex vivo biodistribution
and in vivo imaging values. For imaging time points, ROIs were drawn on the coronal,
sagittal, and transverse slices and the middle median value was tabulated for each
mouse, the average of the four mice are shown with the standard deviation. Values
from previous studies were used as reported.
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Figure S8. Comparison of tumor:tissue ratios at 4 h and 24 h to previous studies: A)
PC3 at 4 h; B) PC3 at 24 h; C) LNCaP at 4 and 24 h.
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SUPPORTING INFORMATION TABLES

Table S1. General specific activities of tracers produced for this study. aApproximated
from the amount of total peptide added. bCalculated from the UV/vis standard
concentration curve. cIn a separate experiment, a specific activity of 1656 μCi/nmol
was attained, but the lower specific activity material was used in the studies in order to
be comparable throughout.
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DATA FOR EACH TRACER FROM THIS STUDY IN FEMALE, BALB/C
MICE WITH ORTHOTOPIC 4T1 BREAST CANCER ALLOGRAFTS
64

Cu-NOTA-WT

Table S1-1. Tissue uptake (mean %ID ± SD) of 64Cu-NOTA-WT administered via the
lateral tail vein in female, BALB/c mice with orthotopic 4T1 breast cancer allografts
implanted into the mammary fat pad.
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Table S1-2. Tissue uptake (mean %ID/g ± SD) of

64

Cu-NOTA-WT administered via

the lateral tail vein in female, BALB/c mice with orthotopic 4T1 breast cancer
allografts implanted into the mammary fat pad.
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Fig. S1-1. Tissue uptake (mean %ID/g ± SD) of

64

Cu-NOTA-WT (n = 4 (3 at 24 h))

administered via the lateral tail vein in female, BALB/c mice with orthotopic 4T1
breast cancer allografts implanted into the mammary fat pad full graph from text.
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Fig. S1-2. HPLC Chromatogram of the Reconstituted 64Cu-NOTA-WT Injectate
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64

Cu-NOTA-Var3

Table S2-1. Tissue uptake (mean %ID ± SD) of

64

Cu-NOTA-var3 administered via

the lateral tail vein in female, BALB/c mice with orthotopic 4T1 breast cancer
allografts implanted into the mammary fat pad.
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Table S2-2. Tissue uptake (mean %ID/g ± SD) of 64Cu-NOTA-Var3 administered via
the lateral tail vein in female, BALB/c mice with orthotopic 4T1 breast cancer
allografts implanted into the mammary fat pad.
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Fig. S2-1. Tissue uptake (mean %ID/g ± SD) of

64

Cu-NOTA-Var3 (n = 5 (4 at 4 h))

administered via the lateral tail vein in female, BALB/c mice with orthotopic 4T1
breast cancer allografts implanted into the mammary fat pad full graph from text.
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Fig. S2-2. HPLC Chromatogram of the Reconstituted 64Cu-NOTA-Var3 Injectate
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64

Cu-NOTA-Var7

Table S3-1. Tissue uptake (mean %ID ± SD) of

64

Cu-NOTA-var7 administered via

the lateral tail vein in female, BALB/c mice with orthotopic 4T1 breast cancer
allografts implanted into the mammary fat pad.
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Table S3-2. Tissue uptake (mean %ID/g ± SD) of 64Cu-NOTA-Var7 administered via
the lateral tail vein in female, BALB/c mice with orthotopic 4T1 breast cancer
allografts implanted into the mammary fat pad.
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Fig. S3-1. Tissue uptake (mean %ID/g ± SD) of

64

Cu-NOTA-var7 (n = 4)

administered via the lateral tail vein in female, BALB/c mice with orthotopic 4T1
breast cancer allografts implanted into the mammary fat pad full graph from text.
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Fig. S3-2. HPLC Chromatogram of the Reconstituted 64Cu-NOTA-Var7 Injectate
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18

F-AlF-NOTA-WT

Table S4-1. Tissue uptake (mean %ID ± SD) of 18F-AlF-NOTA-WT administered via
the lateral tail vein in female, BALB/c mice with orthotopic 4T1 breast cancer
allografts implanted into the mammary fat pad.
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Table S4-2. Tissue uptake (mean %ID/g ± SD) of

18

F-AlF-NOTA-WT administered

via the lateral tail vein in female, BALB/c mice with orthotopic 4T1 breast cancer
allografts implanted into the mammary fat pad.
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Fig. S4-1. Tissue uptake (mean %ID/g ± SD) of

18

F-AlF-NOTA-WT (n = 5)

administered via the lateral tail vein in female, BALB/c mice with orthotopic 4T1
breast cancer allografts implanted into the mammary fat pad full graph from text.
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Fig. S4-2. HPLC Chromatogram of the Reconstituted 18F-AlF-NOTA-WT Injectate

107

18

F-AlF-NOTA-Var3

Table S5-1. Tissue uptake (mean %ID ± SD) of

18

F-AlF-NOTA-Var3 administered

via the lateral tail vein in female, BALB/c mice with orthotopic 4T1 breast cancer
allografts implanted into the mammary fat pad.
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Table S5-2. Tissue uptake (mean %ID/g ± SD) of

18

F-AlF-NOTA-Var3 administered

via the lateral tail vein in female, BALB/c mice with orthotopic 4T1 breast cancer
allografts implanted into the mammary fat pad.
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Fig. S5-1. Tissue uptake (mean %ID/g ± SD) of

18

F-AlF-NOTA-Var3 (n = 5 (4 at 4

h)) administered via the lateral tail vein in female, BALB/c mice with orthotopic 4T1
breast cancer allografts implanted into the mammary fat pad full graph from text.
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Fig. S5-2. HPLC Chromatogram of the Reconstituted 18F-AlF-NOTA-Var3 Injectate
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18

F-AlF-NOTA-Var7

Table S6-1. Tissue uptake (mean %ID ± SD) of

18

F-AlF-NOTA-Var7 administered

via the lateral tail vein in female, BALB/c mice with orthotopic 4T1 breast cancer
allografts implanted into the mammary fat pad.
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Table S6-2. Tissue uptake (mean %ID/g ± SD) of

18

F-AlF-NOTA-Var7 administered

via the lateral tail vein in female, BALB/c mice with orthotopic 4T1 breast cancer
allografts implanted into the mammary fat pad.
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Fig. S6-1. Tissue uptake (mean %ID/g ± SD) of

18

F-AlF-NOTA-Var7 (n = 5)

administered via the lateral tail vein in female, BALB/c mice with orthotopic 4T1
breast cancer allografts implanted into the mammary fat pad full graph from text.
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Fig. S6-2. HPLC Chromatogram of the Reconstituted 18F-AlF-NOTA-Var7 Injectate
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64

Cu-NO2A-cysWT

Table S7-1. Tissue uptake (mean %ID ± SD) of 64Cu-NO2A-cysWT administered via
the lateral tail vein in female, BALB/c mice with orthotopic 4T1 breast cancer
allografts implanted into the mammary fat pad.
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Table S7-2. Tissue uptake (mean %ID/g ± SD) of

64

Cu-NO2A-cysWT administered

via the lateral tail vein in female, BALB/c mice with orthotopic 4T1 breast cancer
allografts implanted into the mammary fat pad.
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Fig. S7-1. Tissue uptake (mean %ID/g ± SD) of

64

Cu-NO2A-cysWT (n = 3-5)

administered via the lateral tail vein in female, BALB/c mice with orthotopic 4T1
breast cancer allografts implanted into the mammary fat pad full graph from text.
Glucose was administered i.p. 30 min prior to tracer injection.
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Fig. S7-2. HPLC Chromatogram of the Reconstituted 64Cu-NO2A-cysWT Injectate
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64

Cu-NO2A-cysVar7

Table S8-1. Tissue uptake (mean %ID ± SD) of

64

Cu-NO2A-cysVar7 administered

via the lateral tail vein in female, BALB/c mice with orthotopic 4T1 breast cancer
allografts implanted into the mammary fat pad.
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Table S8-2. Tissue uptake (mean %ID/g ± SD) of

64

Cu-NO2A-cysVar7 administered

via the lateral tail vein in female, BALB/c mice with orthotopic 4T1 breast cancer
allografts implanted into the mammary fat pad.

121

Fig. S8-1. Tissue uptake (mean %ID/g ± SD) of

64

Cu-NO2A-cysVar7 (n = 4-5)

administered via the lateral tail vein in female, BALB/c mice with orthotopic 4T1
breast cancer allografts implanted into the mammary fat pad full graph from text.
Glucose was administered i.p. 30 min prior to tracer injection.
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Fig. S8-2. HPLC Chromatogram of the Reconstituted 64Cu-NO2A-cysVar7 Injectate

123

18

F-AlF-NO2A-cysWT

Table S9-1. Tissue uptake (mean %ID ± SD) of

18

F-AlF-NO2A-cysWT administered

via the lateral tail vein in female, BALB/c mice with orthotopic 4T1 breast cancer
allografts implanted into the mammary fat pad.
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Table S9-2. Tissue uptake (mean %ID/g ± SD) of

18

F-AlF-NO2A-cysWT

administered via the lateral tail vein in female, BALB/c mice with orthotopic 4T1
breast cancer allografts implanted into the mammary fat pad.
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Fig. S9-1. Tissue uptake (mean %ID/g ± SD) of

18

F-AlF-NO2A-cysWT (n = 4)

administered via the lateral tail vein in female, BALB/c mice with orthotopic 4T1
breast cancer allografts implanted into the mammary fat pad full graph from text.
Glucose was administered i.p. 30 min prior to tracer injection.
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Fig. S9-2. HPLC Chromatogram of the Reconstituted 18F-AlF-NO2A-cysWT Injectate
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18

F-AlF-NO2A-cysVar7

Table S10-1. Tissue uptake (mean %ID ± SD) of

18

F-AlF-NO2A-cysVar7

administered via the lateral tail vein in female, BALB/c mice with orthotopic 4T1
breast cancer allografts implanted into the mammary fat pad.

128

Table S10-2. Tissue uptake (mean %ID/g ± SD) of

18

F-AlF-NO2A-cysVar7

administered via the lateral tail vein in female, BALB/c mice with orthotopic 4T1
breast cancer allografts implanted into the mammary fat pad.
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Fig. S10-1. Tissue uptake (mean %ID/g ± SD) of

18

F-AlF-NO2A-cysVar7 (n = 3-5)

administered via the lateral tail vein in female, BALB/c mice with orthotopic 4T1
breast cancer allografts implanted into the mammary fat pad full graph from text.
Glucose was administered i.p. 30 min prior to tracer injection.
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Fig. S10-2. HPLC Chromatogram of the Reconstituted
Injectate
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18

F-AlF-NO2A-cysVar7

64

Cu –NO2A-cysVar3

Table S11-1. Tissue uptake (mean %ID ± SD) of

64

Cu-NO2A-cysVar3 administered

via the lateral tail vein in female, BALB/c mice with orthotopic 4T1 breast cancer
allografts implanted into the mammary fat pad.
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Table S11-2. Tissue uptake (mean %ID/g ± SD) of 64Cu-NO2A-cysVar3 administered
via the lateral tail vein in female, BALB/c mice with orthotopic 4T1 breast cancer
allografts implanted into the mammary fat pad.
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Fig. S11-1. Tissue uptake (mean %ID/g ± SD) of

64

Cu-NO2A-cysVar3 (n = 3-8)

administered via the lateral tail vein in female, BALB/c mice with orthotopic 4T1
breast cancer allografts implanted into the mammary fat pad full graph from text.
Glucose was administered i.p. 30 min prior to tracer injection.
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Fig. S11-2. HPLC Chromatogram of the Reconstituted 64Cu –NO2A-cysVar3 Injectate
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18

F-AlF-NO2A-cysVar3

Table S12-1. Tissue uptake (mean %ID ± SD) of

18

F-AlF-NO2A-cysVar3

administered via the lateral tail vein in female, BALB/c mice with orthotopic 4T1
breast cancer allografts implanted into the mammary fat pad.
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Table S12-2. Tissue uptake (mean %ID/g ± SD) of

18

F-AlF-NO2A-cysVar3

administered via the lateral tail vein in female, BALB/c mice with orthotopic 4T1
breast cancer allografts implanted into the mammary fat pad.
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Fig. S12-1. Tissue uptake (mean %ID/g ± SD) of

18

F-AlF-NO2A-cysVar3 (n = 4-10)

administered via the lateral tail vein in female, BALB/c mice with orthotopic 4T1
breast cancer allografts implanted into the mammary fat pad full graph from text.
Glucose was administered i.p. 30 min prior to tracer injection.
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Fig. S12-2. HPLC Chromatogram of the Reconstituted
Injectate
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18

F-AlF-NO2A-cysVar3

DATA FROM LEAD TRACERS IN OTHER TUMOR MODELS
64

Cu-NO2A-cysVar3 in PC3 tumor-bearing male nude mice

Table S13-1. Tissue uptake (mean %ID ± SD) of

64

Cu-NO2A-cysVar3 administered

via the lateral tail vein in male, nude mice with shoulder PC3 (prostate cancer)
xenografts.
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Table S13-2. Tissue uptake (mean %ID/g ± SD) of 64Cu-NO2A-cysVar3 administered
via the lateral tail vein in male, nude mice with shoulder PC3 (prostate cancer)
xenografts.
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64

Cu-NO2A-cysVar3 in LNCaP tumor-bearing male nude mice

Table S13-3. Tissue uptake (mean %ID ± SD) of

64

Cu-NO2A-cysVar3 administered

via the lateral tail vein in male, nude mice with shoulder LNCaP (prostate cancer)
xenografts.
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Table S13-4. Tissue uptake (mean %ID/g ± SD) of 64Cu-NO2A-cysVar3 administered
via the lateral tail vein in male, nude mice with shoulder LNCaP (prostate cancer)
xenografts.
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64

Cu-NO2A-cysVar3 in B16-F10 tumor-bearing female C57Bl/6 mice

Table S13-5. Tissue uptake (mean %ID ± SD) of

64

Cu-NO2A-cysVar3 administered

via the lateral tail vein in female, C57Bl/6 mice with orthotopic B16-F10 (melanoma)
allografts.
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Table S13-6. Tissue uptake (mean %ID/g ± SD) of 64Cu-NO2A-cysVar3 administered
via the lateral tail vein in female, C57Bl/6 mice with orthotopic B16-F10 (melanoma)
allografts.
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18

F-AlF-NO2A-cysVar3 in PC3 tumor-bearing male nude mice

Table S13-7. Tissue uptake (mean %ID ± SD) of

18

F-AlF-NO2A-cysVar3

administered via the lateral tail vein in male, nude mice with shoulder PC3 (prostate
cancer) xenografts.
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Table S13-8. Tissue uptake (mean %ID/g ± SD) of

18

F-AlF-NO2A-cysVar3

administered via the lateral tail vein in male, nude mice with shoulder PC3 (prostate
cancer) xenografts.
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18

F-AlF-NO2A-cysVar3 in LNCaP tumor-bearing male nude mice

Table S13-9. Tissue uptake (mean %ID ± SD) of

18

F-AlF-NO2A-cysVar3

administered via the lateral tail vein in male, nude mice with shoulder LNCaP
(prostate cancer) xenografts.
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Table S13-10. Tissue uptake (mean %ID/g ± SD) of

18

F-AlF-NO2A-cysVar3

administered via the lateral tail vein in male, nude mice with shoulder LNCaP
(prostate cancer) xenografts.
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18

F-AlF-NO2A-cysVar3 in B16-F10 tumor-bearing female C57Bl/6 mice

Table S13-11. Tissue uptake (mean %ID ± SD) of

18

F-AlF-NO2A-cysVar3

administered via the lateral tail vein in female, C57Bl/6 mice with orthotopic B16-F10
(melanoma) allografts and one group of female, BALB/c mice with orthotopic B16F10 (melanoma) allografts at 6 h. *BALB/c time point.
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Table S13-12. Tissue uptake (mean %ID/g ± SD) of

18

F-AlF-NO2A-cysVar3

administered via the lateral tail vein in female, C57Bl/6 mice with orthotopic B16-F10
(melanoma) allografts and one group of female, BALB/c mice with orthotopic B16F10 (melanoma) allografts at 6 h. *BALB/c time point.
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18

F-AlF-NO2A-cysVar3 in U87MG tumor-bearing male nude mice

Table S13-13. Tissue uptake (mean %ID ± SD) of

18

F-AlF-NO2A-cysVar3

administered via the lateral tail vein in male, nude mice with U87MG xenografted
flank tumors at 6 h. *BALB/c time point.
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Table S13-14. Tissue uptake (mean %ID/g ± SD) of

18

F-AlF-NO2A-cysVar3

administered via the lateral tail vein in male, nude mice with U87MG xenografted
flank tumors at 6 h. *BALB/c time point.
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Significance Statement
Two aspects of contemporary cancer chemotherapy are targeted therapy and targeted
delivery. While there are many examples of targeted therapy, targeted delivery has
been limited due to its reliance on tumor cell biomarkers, either in the form of antigens
or of specific binding sites; because of the dependence on the presence of these
suitable biomarkers and because of high tumor heterogeneity, targeted delivery has not
shown great success so far. The emergence of pHLIP technology provides an
alternative by targeting a metabolic marker: tumor cell surface acidity. While
promising, the technology is still developing and advances could have a significant
impact on therapy. Here, we report several new pHLIPs, including pHLIP bundles, a
new concept, and we thoroughly evaluate these constructs alongside a new generation
of pHLIPs. We also discuss challenges inherent to the design and accurate evaluation
of pHLIPs. Our research elucidates the strengths and weaknesses of existing pHLIPs,
proposes future peptide modifications that could further improve tumor targeting, and
discusses the applicability of this new generation of pHLIPs for specific areas of drug
delivery. These principles and new constructs promise increasing success in tumor
therapy.
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Abstract
pH (Low) Insertion Peptides (pHLIPs) target acidity at the surfaces of cancer cells and
show utility in a wide range of applications including tumor imaging and the
intracellular delivery of therapeutic agents. Here we report new pHLIP constructs that
significantly improve the targeted delivery of agents into tumor cells. The new
constructs include pHLIP bundles (conjugates consisting of two or four pHLIP
peptides linked by polyethelyne glycol) and Var3 pHLIPs containing either the nonstandard amino acid γ-carboxyglutamic acid or a glycine-leucine-leucine motif. The
performance of the new constructs in vitro and in vivo was compared with previous
pHLIP variants. A wide range of experiments was performed on nine constructs
including: i) biophysical measurements using steady-state and kinetic fluorescence
spectroscopy, circular dichroism (CD) spectroscopy, and oriented circular dichroism
(OCD) spectroscopy to study the pH-dependent insertion of pHLIP variants across the
membrane lipid bilayer; ii) cell viability assays to gauge the pH-dependent potency of
peptide-toxin constructs by assessing the intracellular delivery of the polar, cellimpermeable cargo molecule amanitin at physiological and low pH (pH 7.4 and 6.0,
respectively); and iii) tumor targeting and biodistribution measurements using
fluorophore-peptide conjugates in a breast cancer mouse model. The main principles
of the design of pHLIP variants for a range of medical applications are discussed.
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Introduction
The targeted delivery of drugs to cancer cells promises to maximize their therapeutic
effects while reducing side effects. Although many biomarkers exist that can be
exploited to improve tumor targeting and treatment outcomes, such as various
receptors overexpressed at the surfaces of some cancer cells, useful markers are not
present in all tumors. Further, the heterogeneity of the cancer cell population in an
individual tumor and between tumors of various patients limits the effective use of
biomarker targeting technologies, and rapid mutation increases the likelihood of the
selection of cancer cell phenotypes that do not express high levels of the targeted
biomarker. Thus, biomarker targeting can act as a selection method that may lead to
the development of drug resistance and poor patient outcomes (1-3).
It is well known that acidosis is ubiquitous in tumors, including both primary
tumors and metastases, as a consequence of their rapid metabolism (4). The acidic
microenvironment is generated by the increased use of glycolysis by cancer cells, and
by the abundance of carbonic anhydrase proteins on the cancer cell surfaces. Tumor
cells stabilize their cytoplasmic pH by exporting the acidity to the extracellular
environment. As a result of the proton flux and resulting membrane potential, the
extracellular pH is lowest at the surfaces of cancer cells, where it is significantly lower
than both the normal physiological pH and the bulk extracellular pH in tumors (5-7).
The low pH region persists at the cancer cell surface even in well-perfused tumor
areas. The acidity on the surfaces of cancer cells is a targetable characteristic that is
not subject to clonal selection, and the level of acidity is a predictor of tumor invasion
and aggression since more rapidly growing tumor cells are more acidic.
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The emerging technology based on pH (low) insertion peptides (pHLIPs)
comprises a variety of acidity-targeting peptides, each possessing different tumortargeting characteristics. pHLIPs can be used in a wide variety of applications, so it is
desirable to have a range of options available for use in specific applications. Some
examples of these applications include: i) fluorescence imaging (8-10) and
fluorescence image-guided surgery (11); ii) nuclear imaging, including positron
emission tomography (PET) and single-photon emission computed tomography
(SPECT) (12, 13); iii) therapy, including the targeted delivery of polar toxins that
cannot cross cell membranes (14, 15), drug-like molecules that inherently diffuse
across cell membranes (16, 17), and gene therapy (18); and iv) nanotechnology, in
which pHLIP is used to enhance the delivery of gold nanoparticles (19, 20) or
liposome-encapsulated payloads to cancer cells (21).
pHLIPs are triggered to insert across the membranes of cancer cells by the
acidity at the cancer cell surface. The behavior of peptides in the pHLIP family is
typically described in terms of three states: at physiological pH (pH 7.4), peptides
exist in equilibrium between a solvated state (State I) and a membrane-adsorbed state
(State II); a decrease in pH shifts the equilibrium toward a membrane-inserted state
(State III) (22). The mechanism of action of peptides in the pHLIP family is well
understood: protonatable residues, which are interspersed throughout the hydrophobic
middle region and the C-terminal, membrane-inserting region of the peptides, are
negatively charged at physiological pH but become neutralized by protonation with a
decrease in pH. The loss of charge and increase in overall hydrophobicity drives
pHLIPs to partition across the hydrophobic core of the membrane bilayer to form a
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transmembrane helix. This helix spans the lipid bilayer, leaving the N-terminus in the
extracellular space and placing the C-terminus in the intracellular space where, due to
the more alkaline pH in the cytosol, the C-terminus can again become deprotonated
and charged, stably anchoring the peptide in the cell membrane.
Following an extensive characterization of wild-type (WT) pHLIP, a firstgeneration of pHLIP variants was created to examine the effects on targeting due to
fairly straightforward changes to the WT primary structure such as sequence
truncation, the addition and replacement of some protonatable residues with others,
and sequence reversal (23-25). Importantly, a number of the changes that were
investigated had adverse effects on pHLIP properties, suggesting that further studies
might reveal design principles and give more useful molecules for targeted therapy. Of
these first-generation variants, Variant 3 (Var3) appeared to have the most desirable
insertion characteristics and much research has been focused on the use of Var3 for
various applications (10, 11, 26, 27).
Lately, new variants have emerged that incorporate more innovative changes to
the peptide primary structure; these changes include the use of the non-standard amino
acids γ-carboxyglutamic acid (Gla), a residue with two protonatable carboxyl groups,
and α-aminoadipic acid (Aad), a more hydrophobic version of the glutamic acid
residue (28), as well as the creation of a pHLIP peptide de novo, ATRAM (29). Here,
we examine several new members of the pHLIP family of peptides, including pHLIP
bundles, compare their biophysical properties to some of the previous generation
variants, and evaluate the utility of nine pHLIPs in drug delivery and tumor imaging
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applications. These variants significantly expand the useful range of applications in
targeted cancer therapy.

Results
pHLIP constructs. We have designed two new pHLIP variants, Var3/Gla
(incorporating the non-standard amino acid Gla) and Var3/GLL (utilizing a glycineleucine-leucine motif), and a novel construct: pHLIP bundles. pHLIP bundles consist
of two- or four-armed 2 kDa polyethylene glycol (PEG) spacers conjugated to the
cysteine residue at the N-terminus of WT: PEG-2WT (Figure 1a) and PEG-4WT
(Figure 1b), respectively. Our motivation is to increase both the membrane affinity
and the cooperativity of the transition from the membrane-surface state to the
membrane-inserted state. Enhancement of affinity is expected to improve targeting,
and higher cooperativity should narrow the pH window that produces transmembrane
drug delivery. The nine pHLIP variants studied (molecular weights and retention times
are provided in Table S2) were as follows, with additional variations from the addition
of single N- or C-terminal cysteine or lysine residues for conjugation purposes (a list
of all peptides investigated is provided in Table S1):

WT:

AEQNPIYWARYADWLFTTPLLLLDLALLVDADEGT

PEG-2WT:

Two-arm PEG conjugated to two WT pHLIPs

PEG-4WT:

Four-arm PEG conjugated to four WT pHLIPs

WT/Gla:

AEQNPIYWARYAGlaWLFTTPLLLLDLALLVDADEGT
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WT/Gla/Aad:

AEQNPIYWARYAGlaWLFTTPLLLLAadLALLVDADEGT

Var3:

ADDQNPWRAYLDLLFPTDTLLLDLLW

Var3/Gla:

ADDQNPWRAYLGlaLLFPTDTLLLDLLW

Var3/GLL:

GEEQNPWLGAYLDLLFPLELLGLLELGLWG

ATRAM:

GLAGLAGLLGLEGLLGLPLGLLEGLWLGLELEGN

These pHLIP variants can be grouped together in various ways by shared
characteristics. A WT-like group contains peptides with two protonatable residues
(shown in bold) in the underlined putative transmembrane (TM) region, multiple
protonatable residues in the membrane-inserting C-terminal region, and two
tryptophan residues (residue W) located at the beginning of the helix-forming TM
region; this group includes WT, PEG-2WT and PEG-4WT, WT/Gla, and
WT/Gla/Aad. A Var3-like group is based on Var3 from the first generation of pHLIP
variants (25). This group includes Var3, Var3/Gla and Var3/GLL, each of which have
three protonatable residues in the TM region and tryptophan residues located at the
beginning and end of the TM region. Considering this scheme, ATRAM, with its
multiple glycine and leucine residues and single tryptophan located about two-thirds
of the way through its TM region, is in a group of its own. Other subgroups can be
considered as well: a subgroup of peptides that incorporate the non-standard Gla
residue, shown in italics (i.e., WT/Gla, WT/Gla/Aad, and Var3/Gla), and another
subgroup that includes peptides containing the GLL motif (Var3/GLL and ATRAM).
When performing analysis of biophysical measurements, analyzing variants
with respect to their group-mates becomes important: the very different characteristics
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of peptides from various groups make it difficult to accurately compare the behavior
of all peptides at the same time.

Biophysical steady-state and kinetics studies. A variety of spectroscopic techniques
were employed to probe the interaction between pHLIP variants and POPC
phospholipid bilayers in liposomes; these techniques included steady-state
fluorescence spectroscopy, circular dichroism (CD) spectroscopy, oriented circular
dichroism (OCD) spectroscopy, and stopped-flow fluorescence measurements. Steadystate fluorescence and CD experiments were conducted in phosphate buffer titrated
with hydrochloric acid to drop the pH from pH 8 to pH 4 to ensure consistency with
previously published data (25, 29, 30). Steady-state and kinetics fluorescence
experiments measuring the pH-dependent transition from State II to State III were
carried out in phosphate buffer containing physiological concentrations of calcium
(1.25 mM) and magnesium (0.65 mM) ions (the concentrations at which free calcium
and magnesium ions are found in the blood), since we conjectured that some of the
studied constructs might interact with these ions, and that this interaction might
significantly affect the ultimate in vivo performance of the peptides.
We established that, in solution, PEG-2WT and PEG-4WT most probably exist
in compact coil conformations, where tryptophan and other aromatic residues can
form stacking structures. The resulting exciton formation was seen as a minimum
around 230 nm in the CD spectra of these pHLIP bundles (Figure 1e and 1f). At pH 8,
changes in tryptophan fluorescence show that both constructs interact with the lipid
bilayer and it appears that PEG-4WT exhibits stronger binding than PEG-2WT in
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State II. With a reduction of pH, both pHLIP bundles inserted into the bilayer to form
helices, and the transmembrane orientations of these helices were confirmed by OCD
measurements (Figure 1g and 1h). It is important to note that in State III, the
membrane-inserted state, the exciton signal generated by π-π stacking is no longer
present, suggesting that the insertion of each pHLIP renders it independent of the
other(s). The apparent pK of the transition from State II to State III was shifted to pH
6.6 and, as might be expected, the cooperativity of the transition was increased for
PEG-4WT compared to PEG-2WT (Figure 1i and 1j).
We compared the groups consisting of WT, Var3, and ATRAM pHLIP
variants to the newly designed Var3/Gla and Var3/GLL pHLIP variants. The retention
times of the peptides indicate increasing hydrophobicity within the groups in the
following order, from less to more hydrophobic: WT, WT/Gla, WT/Gla/Aad and
Var3, Var/Gla, Var3/GLL, and ATRAM, with ATRAM being the most hydrophobic
(Table S2). Both new pHLIP variants, Var3/Gla and Var3/GLL, demonstrated a pHdependent interaction with the membrane (Figure S1). Var3/GLL showed a higher
percentage of membrane-inserted population at pH 8, which reflects a higher affinity
of the peptide for the lipid bilayer both at physiological and high pH due to the
increased hydrophobicity of the peptide.
As seen for previous pHLIP designs, a blue shift (or decrease in Stokes shift)
resulting from the environmental changes from State I to State II and State III was
observed for all peptides (Table S3), indicating partitioning of the peptides into the
lipid bilayer. However, we cannot directly compare the positions of fluorescence
spectra maxima for peptides belonging to the different groups, since the locations of
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the tryptophan residues within the peptides varies greatly. With this fact in mind, we
can conclude that the peptides had very different conformations in State II at pH 8,
and that the highest membrane affinity was exhibited by the PEG-pHLIPs and by the
WT/Gla/Aad, Var3/GLL, and ATRAM peptides. The PEG-pHLIPs have multiple
binding sites due to the linking of multiple WT peptides within a single construct,
which is expected to enhance binding affinity. The WT/Gla/Aad, Var3/GLL, and
ATRAM have the most hydrophobic sequences, and thus exhibit strong
binding/insertion. We also found that some peptides were especially sensitive to the
presence of calcium and magnesium ions, namely WT, variants containing the Gla
residue (WT/Gla, WT/Gla/Aad, and Var3/Gla) and ATRAM. This sensitivity was
most obviously seen as a decreased Stokes shift (usually 2-3 nm) in State I and/or
State II, and might reflect slight increases in the hydrophobicity of the peptides caused
by the coordination of divalent cations resulting from the presence of closely spaced
protonatable residues, such as those found in the C-terminal region of WT and, to
some degree, in ATRAM, or to the presence of the Gla residue, with its two
protonatable carboxyl groups, in the WT/Gla, WT/Gla/Aad, and Var3/Gla peptides. It
is known that a Gla residue can form a complex with a calcium ion (31-33). The
decrease in Stokes shift in State II is likely due to the location of membrane-adsorbed
peptides deeper in the lipid membrane (especially for the more hydrophobic pHLIPs:
WT/Gla/Aad, Var3/GLL, and ATRAM) and/or a shift in peptide population from the
solvated to the membrane-adsorbed state.
In contrast to tryptophan fluorescence changes, which are dependent on the
location of tryptophan residues within the peptide sequence, the appearance of helicity
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is a more general parameter which can be compared among all peptides. In Figure 2a
(and Table S3), we give the ratio of ellipticity at 205 nm to 222 nm, an indicator of the
degree of helicity (lower ratios indicate higher helicity), obtained for different peptides
in different states. In State I, the lowest ratios were observed for pHLIP bundles,
which correlate with the appearance of the exciton signal at 230 nm. In State II, the
least unstructured peptides (ratio <1.5) were PEG-4WT, WT/Gla/Aad, Var3/GLL,
ATRAM, and PEG-2WT, which exhibited a higher affinity to the membrane and an
increase in the peptide-inserted population at pH 8. At low pH, all peptides exhibited
similar helical content, as expected from the observed formation of TM helices.
The transitions from State II to State III seen in steady-state and kinetics modes
exhibited pK values in the range of pH 5.7 to 6.6 in the presence of physiological
concentrations of calcium and magnesium ions, with the highest cooperativity
observed for PEG-4WT, and transition times varying from 0.1 to 37.5 s (Table 1).
There are subtleties that affect the comparison and interpretation of the data: i) the
peptides are in different starting conditions in State II at pH 8 due to greatly differing
overall peptide hydrophobicity; ii) pK values and characteristic times report the
movement of tryptophan residues into environments inside the membrane; however,
since the tryptophan residues are located in different regions of each pHLIP, their
propagation into the membrane as measured via changes in fluorescence parameters
should be expected to be different; and iii) the cooperativity of the transition is a
somewhat unstable parameter in the fitting of experimental pH-dependence data using
the Henderson-Hasselbalch equation, especially if slopes are introduced at the
initiation and completion of the transition (34). Low values of cooperativity (n <1)
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were observed for the peptides with tryptophan residues located at (Var3 group) or
close (ATRAM) to the C-terminus, which must be translocated across the cell
membrane. ATRAM and Var3/GLL, which are the most hydrophobic pHLIPs and are
therefore likely to be located more deeply than others in the membrane at pH 8,
demonstrated the fastest times of insertion. As we showed previously, the removal of
protonatable residues from the inserting C-terminus increases the rate of the transition
from State II to State III (24, 25). Thus, the group of Var3-like peptides exhibited fast
insertion times (t <1 s). In the group of WT peptides, the time of insertion decreased as
the hydrophobicity of the peptide increased, with insertion times listed in the
following order (from longest to shortest time of insertion): WT, WT/Gla,
WT/Gla/Aad, PEG-2WT, and PEG-4WT.

Intracellular delivery of polar cargo. Before studying the toxicity of pHLIP-toxin
conjugates, we investigated whether the pHLIP bundles could cause any acute
cytotoxicity by themselves. HeLa cells were treated with either PEG-2WT or PEG4WT at physiological pH (pH 7.4) and low pH (pH 6.0) for two hours. We did not
observe any cytotoxic effect at either pH, even when treating with concentrations up to
10 µM (construct concentration is presented as concentration of WT pHLIP).
A proliferation assay was employed to evaluate the ability of pHLIPs to deliver
the amanitin toxin, a relatively cell-impermeable, polar cargo molecule (35, 36). For
amanitin to induce cytotoxicity it must be translocated across the cell membrane, be
released from its peptide carrier, and reach its target in the nucleus (RNA polymerase
II). Amanitin was conjugated via a cleavable disulfide link to the inserting, C-termini
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of the peptides. The translocation capabilities of the pHLIP-amanitin conjugates were
measured as the inhibition of proliferation of HeLa cells due to treatment with
increasing concentrations (up to 2 µM) of pHLIP-amanitin at either physiological pH
(pH 7.4) or low pH (pH 6.0) for two hours, followed by removal of the constructs,
transfer of cells to normal cell culture media, and assessment of cell death at 48 hours.
Each of the conjugates demonstrated pH-dependent cytotoxicity (Figure S2).
The calculated EC20, EC50, and EC80 at physiological and low pH are shown in Table
1. At low pH, the most potent constructs were the pHLIP bundles, which exhibited the
highest cooperativity of insertion into the membrane. The least toxic at normal pH
among all constructs was Var3. Figure 2b lists the therapeutic indexes (TI), defined as
the ratio of EC50 at pH 7.4 to EC50 at pH 6.0 for each case. A TI of about 9 was
obtained for WT/Gla and Var3, and the TI was around 5.5 for PEG-2WT, Var3/Gla
and ATRAM. It is also desirable to have high potency, which is defined as the
difference between cell viability at low and physiological pHs at different
concentrations of the construct (Figure 3). All constructs had high potency (60-70%)
at particular concentrations; however, just a few constructs, namely Var3, Var3/Gla,
and WT/Gla, had a high, stable potency over a wide range of concentrations. pHLIP
bundles displayed the highest potency at the lowest concentrations (0.1-0.2 µM). The
potency of ATRAM peaked at concentrations around 0.5 µM and declined sharply at
higher concentrations; this decline is most likely associated with the increased
hydrophobicity of ATRAM, which results in a high affinity to the cell membrane at
normal and high pH and promotes the shift in equilibrium toward the membrane-
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inserted form that is associated with the translocation of cargo across the cell
membrane.

Tumor targeting. To evaluate the tumor targeting and biodistribution characteristics
of the pHLIP variants, we conjugated the fluorescent dye Alexa Fluor 546 (AF546) to
the non-inserting, N-termini of seven of the peptides. Our previous data indicate
excellent tumor targeting by AF546-pHLIPs (9, 27). In the case of pHLIP bundles,
AF546 was conjugated to the inserting, C-termini of the PEG-2WT and PEG-4WT
pHLIPs, as the N-termini were occupied by PEG polymers. A well-established mouse
model, using implanted cells of acidic 4T1 murine breast tumors, was used in the
study; this model is targeted well by pHLIPs (9, 27). Following the development of
breast tumors in the mouse flank, each fluorescent construct was introduced by a
single tail vein injection. Animals were euthanized four hours after the injection of the
fluorescent conjugates, and the tumor and major organs (kidney, liver, lungs, spleen,
and muscle) were collected and imaged. We selected the four-hour post-injection time
point based on previous pharmacokinetics data which show that the highest tumor
targeting of pHLIPs is observed four hours after the injection of construct (9, 27). The
mean values of the surface fluorescence intensity of tumors, muscle, and organs are
given in Table S4. The normalized tumor fluorescence intensity (normalized by tumor
uptake of AF546-WT) for all constructs is shown in Figure 4a. The highest tumor
targeting was observed for the Var3 construct, as well as for Var3/Gla and ATRAM.
The tumor uptakes of the WT and Var3/GLL constructs were significantly reduced, by
1.6- and 2.6-fold, respectively, compared to the uptake of Var3. The uptakes of
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WT/Gla, WT/Gla/Aad, and the pHLIP bundles were reduced even further compared to
the uptake of the WT construct. It is possible that the decreased tumor targeting
observed in the PEG-pHLIP bundles might be attributed to the fact that the AF546 dye
was conjugated to the C-terminus, which is translocated into the cytosol. At the same
time, the tumor-to-muscle ratio of the WT-like group was in the range of 5.4-7.5. The
highest tumor-to-muscle ratios were observed for Var3 (T/M=8.9) and PEG-2WT
(T/M=7.5), and the lowest ratio was observed in Var3/GLL (T/M=4.0) (Figure 4b and
Table S5). Among all constructs, only Var3/GLL demonstrated a tumor-to-kidney
ratio less than 1 (Figure 4c and Table S5). The highest tumor-to-liver ratio was found
in Var3 and Var3/Gla (Figure 4d and Table S5).
Because PEG-2WT-AF546 and PEG-4WT-AF546 are several times larger
than the other pHLIP variants, we hypothesized that they might have slower
pharmacokinetics. Therefore, we also performed imaging at the 24-hour post-injection
time point for the two PEG-pHLIP conjugates; however, we did not observe any
significant signal increase in tumors at 24 hours post-injection compared to 4 hours
post-injection (Table S4).

Discussion
In order to advance cancer therapy using a range of agents with different properties,
we have developed new pHIP variants and pHLIP bundles, and compared their
performance to the performance of recently introduced variants with non-standard
amino acids (Gla and Aad) and the hydrophobic glycine-leucine-leucine (GLL) motif.
Our goal was to correlate the biophysical properties of the membrane interactions of
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different pHLIPs, including physiological concentrations with free calcium and
magnesium ions, to the ability of these pHLIPs to move polar cargo across the cell
membrane and to target acidic tumors.
The insertion pK and cooperativity parameters of the steady-state, pHdependent transition from State II at pH 8 to State III at pH <5 can be taken as
predictors of the performance of a pHLIP for drug delivery and tumor targeting (17,
28, 29). While pK is a rather stable fitting parameter, the cooperativity parameter (Hill
coefficient) might vary over a wide range resulting from different fittings which are
within the level of accuracy of the experimental measurements. Moreover, if different
binding affinities are assumed, the Hill model loses validity. In general, highly
cooperative transitions are hard to measure in biological systems with noise, especially
when examining relatively short peptides like those that comprise the class of pHLIP
peptides (28). Only if the biological system is approximated to be infinite can a phase
transition occur (37). Moreover, transition parameters for different peptides can only
be truly compared when both peptides have precisely the same starting and ending
states; although this condition is met for the membrane-inserted state (State III) of the
peptides, which appears very similar among pHLIP variants, the condition that the
initial state (State II) of the peptides be identical is not met. As hydrophobicity varies
widely among peptides of the pHLIP family due to the difference in numbers of
protonatable, polar, and hydrophobic residues and their location within the peptide
sequences, the characteristics of the peptide population in the initial state of the
transition also varies as these peptides position themselves at different interaction
levels with the hydrophobic/hydrophilic boundary region of a bilayer.
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The population percentages of inserted peptide presented in Table S6 were
calculated from the pH-dependent transitions of pHLIP variants. The numbers
represent the percentage of membrane-inserted peptides at varying pH assuming that,
at the beginning of the transition (State II) (i.e., at physiological pH and higher), the
population of inserted peptides is close to zero. In reality, close consideration of the
interaction between a pHLIP variant and the membrane at pH 8, in conditions more
alkaline than physiological conditions where the inserted peptide population should be
even less than at physiological conditions, indicates that the most hydrophobic
sequences, such as ATRAM and Var3/GLL, and bundled pHLIPs with multiple
binding sites within a single construct, exhibit a significant inserted peptide
population, as shown by the loss of pH-dependent differences in the translocation of
the polar, cell-impermeable cargo amanitin with an increase in construct concentration
(i.e., a decrease in potency at higher concentrations). Due to patient variability, it is
highly desirable that potential therapeutic pHLIP constructs be able to discriminate
between healthy and tumor tissue over a wide concentration range, meaning that a
constant potency is necessary to avoid targeting normal tissue and the resulting
significant side effects, which suggests that these variants (i.e., ATRAM, Var3/GLL,
and bundled pHLIPs) may not be well suited for clinical development using agents
that require tight targeting.
In addition to the steady-state experiments, it is important to probe tumor
targeting and to examine the biodistribution of the constructs when injected into the
high-flowrate blood stream, since targeted delivery is always diminished by clearance
via the blood. The best tumor targeting was shown by faster-inserting pHLIP
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constructs; thus, in the design of new pHLIP variants, the biophysical kinetics
parameters need to be considered in addition to the more traditionally prioritized
steady-state properties. These kinetics parameters might be especially critical for the
delivery and translocation of a cargo across a membrane, since we have shown that
charges and the presence of cargo at the inserting end of a pHLIP can slow the process
of insertion (24). Different cargoes linked to a pHLIP alter biodistribution and tumor
targeting (27). Less polar pHLIP variants conjugated with hydrophobic cargoes might
have a higher tendency toward targeting normal tissue and hepatic clearance. On the
other hand, the size of links in pHLIP bundles could be used to tune biodistribution
and redirect clearance from renal to hepatic.
Among the pHLIP variants we investigated, Var3 demonstrated excellent
performance in vitro (displaying the most stable potency over a wide range of
concentrations) and in vivo, displaying high tumor targeting. Variants containing the
Gla residue, especially the WT/Gla construct, showed an increase in the cooperativity
of the membrane insertion transition as previously reported (28), and showed an
improved therapeutic index; however, the tumor targeting of WT/Gla was lower
compared to the tumor targeting of WT.
γ-carboxyglutamic acid is not naturally encoded in the human genome, but is
introduced into proteins through the post-translational carboxylation of glutamic acid,
resulting in an amino acid with two carboxyl groups. Many proteins are known to have
Gla-rich domains, including several coagulation factors which, by coordinating
calcium ions, are induced to change conformation and increase their hydrophobicity
and affinity to the cell membrane bilayer (38). Calcium complex formation by a
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pHLIP increases the hydrophobicity of the peptide and alters the interaction between
peptide and membrane; this fact, along with the fact that the cost of synthesizing a
Gla-containing peptide is very high (Gla is one of the most expensive amino acids)
might somewhat reduce enthusiasm for using the Gla residue, although if there were
sufficient advantages in a specific case the cost might be justified. While considering
peptide synthesis, it is worthwhile to note that very hydrophobic pHLIP sequences
(like ATRAM), especially when coupled with even moderately hydrophobic cargoes,
might be challenging to produce in the large quantities needed for clinical translation.
There is no single recipe for the best pHLIP: the peptide will need to be
tailored to each specific medical application. For example, kidney clearance might be
preferred to liver clearance for PET-pHLIP imaging constructs (13). High tumor-tonormal tissue fluorescence intensity ratios will be the key in fluorescence-guided
surgery applications (11). Delivery of highly toxic molecules, such as amanitin, would
require minimal off-targeting, thus high potency and therapeutic index will be critical.
However, for the delivery of polar peptide nucleic acids (PNAs) or other highly
specific inhibitors of particular pathways in cancer cells, neither of which are
associated with toxicity in normal cells, the requirement to reduce off-targeting might
be much lower and the emphasis would be shifted toward the efficiency of delivery,
the goal being to translocate as much cargo as possible (18, 39). pHLIP bundles might
yield excellent results in these types of applications, supported by the observation that
PEG-4WT was the most efficient at delivering the polar molecule amanitin to the
intracellular space. We suspect that bundling multiple Var3 pHLIPs, in the same
fashion that we linked two or four WT pHLIPs, might be even more advantageous.
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Var3 demonstrates membrane insertion rates orders of magnitude faster than the
insertion rates of WT; with the knowledge that faster insertion rates observed in
biophysical experiments correlates to better tumor targeting in vivo, it stands to reason
that potential PEG-Var3 constructs might demonstrate better tumor targeting still.
In drug delivery applications, pHLIP peptides are best designed for the
delivery of polar, cell-impermeable molecules (14, 35, 40, 41). The intracellular
delivery of a polar cargo could be further tuned by altering the link connecting the
cargo to pHLIP and/or by attaching modulator molecules to the inserting end of the
peptide (14, 15, 18, 35). Additionally, pHLIP could be used for the targeted delivery
of cell-permeable, drug-like molecules since it can significantly increase the time of
retention in blood, positively alter the biodistribution of drugs that typically rely on
passive diffusion, and enhance tumor targeting, all of which would lead to an increase
in therapeutic index (16). More polar pHLIP variants are expected to be better suited
to applications involving the intracellular delivery of cell-permeable cargoes.
We have now established a set of properties for a number of pHLIPs, which
can be selected as starting points for clinical development in different circumstances.
This body of work, along with the prior studies, opens pathways for targeted delivery
using a range of imaging and therapeutic agents in the fight against cancer.

Materials and Methods
The details of experimental protocols can be found in Supplementary Materials and
Methods.

175

Acknowledgements
We are grateful to Dr. Dhammika Weerakkody for his assistance and helpful
discussions. The research reported in this publication was supported in part by the
National Institute of General Medical Sciences of the National Institutes of Health
under award number R01GM073857 to OAA, YKR, and DME, and in part by the
Institutional Development Award (IDeA) Network for Biomedical Research
Excellence from the National Institute of General Medical Sciences of the National
Institutes of Health under grant number P20GM103430.

176

References
1.

Marusyk A & Polyak K (2010) Tumor heterogeneity: causes and
consequences. Biochim Biophys Acta 1805(1):105.

2.

Gillies RJ, Verduzco D, & Gatenby RA (2012) Evolutionary dynamics of
carcinogenesis and why targeted therapy does not work. Nat Rev Cancer
12(7):487-493.

3.

Lloyd MC, et al. (2016) Darwinian Dynamics of Intratumoral Heterogeneity:
Not Solely Random Mutations but Also Variable Environmental Selection
Forces. Cancer Res 76(11):3136-3144.

4.

Estrella V, et al. (2013) Acidity generated by the tumor microenvironment
drives local invasion. Cancer Res 73(5):1524-1535.

5.

Zhang X, Lin Y, & Gillies RJ (2010) Tumor pH and its measurement. J Nucl
Med 51(8):1167-1170.

6.

Hashim AI, Zhang X, Wojtkowiak JW, Martinez GV, & Gillies RJ (2011)
Imaging pH and metastasis. NMR Biomed 24(6):582-591.

7.

Anderson M, Moshnikova A, Engelman DM, Reshetnyak YK, & Andreev OA
(2016) Probe for the measurement of cell surface pH in vivo and ex vivo. Proc
Natl Acad Sci USA 113(29):8177-8181.

8.

Reshetnyak YK, et al. (2011) Measuring tumor aggressiveness and targeting
metastatic lesions with fluorescent pHLIP. Mol Imaging Biol 13(6):1146-1156.

9.

Adochite RC, et al. (2014) Targeting breast tumors with pH (low) insertion
peptides. Mol Pharm 11(8):2896-2905.

177

10.

Tapmeier TT, et al. (2015) The pH low insertion peptide pHLIP Variant 3 as a
novel marker of acidic malignant lesions. Proc Natl Acad Sci USA
112(31):9710-9715.

11.

Golijanin J, et al. (2016) Targeted imaging of urothelium carcinoma in human
bladders by an ICG pHLIP peptide ex vivo. Proc Natl Acad Sci USA
113(42):11829-11834.

12.

Macholl S, et al. (2012) In vivo pH imaging with (99m)Tc-pHLIP. Mol
Imaging Biol 14(6):725-734.

13.

Demoin DW, et al. (2016) PET imaging of extracellular pH in tumors with
64Cu- and 18F-labeled pHLIP peptides: A structure-activity optimization
study. Bioconjugate Chem 27(9):2014-2023.

14.

Andreev OA, et al. (2010) pH (low) insertion peptide (pHLIP) inserts across a
lipid bilayer as a helix and exits by a different path. Proceedings of the
National Academy of Sciences 107(9):4081-4086.

15.

Wijesinghe D, Engelman DM, Andreev OA, & Reshetnyak YK (2011) Tuning
a polar molecule for selective cytoplasmic delivery by a pH (Low) Insertion
Peptide. Biochemistry 50(47):10215-10222.

16.

Burns KE, Robinson MK, & Théveninr D (2015) Inhibition of cancer cell
proliferation and breast tumor targeting of pHLIP-monomethyl auristatin E
conjugates. Mol Pharm 12(4):1250-1258.

17.

Burns KE, Hensley H, Robinson MK, & Thevenin D (2017) Therapeutic
efficacy of a family of pHLIP-MMAF conjugates in cancer cells and mouse
models. Mol Pharm 14(2):415-422.
178

18.

Cheng CJ, et al. (2015) MicroRNA silencing for cancer therapy targeted to the
tumor microenvironment. Nature 518(7537):107-110.

19.

Yao L, et al. (2013) pHLIP peptide targets nanogold particles to tumors. Proc
Natl Acad Sci USA 110(2):465-470.

20.

Daniels JL, Crawford TM, Andreev OA, & Reshetnyak YK (2017) Synthesis
and characterization of pHLIP® coated gold nanoparticles. Biochem Biophys
Rep 10:62-69.

21.

Yao L, Daniels J, Wijesinghe D, Andreev OA, & Reshetnyak YK (2013)
pHLIP(®)-Mediated Delivery of PEGylated Liposomes to Cancer Cells. J
Control Release 167(3):228-237.

22.

Reshetnyak YK, Segala M, Andreev OA, & Engelman DM (2007) A
Monomeric Membrane Peptide that Lives in Three Worlds: In Solution,
Attached to, and Inserted across Lipid Bilayers. Biophys J 93(7):2363-2372.

23.

Reshetnyak YK, Andreev OA, Segala M, Markin VS, & Engelman DM (2008)
Energetics of peptide (pHLIP) binding to and folding across a lipid bilayer
membrane. Proc Natl Acad Sci USA 105(40):15340-15345.

24.

Karabadzhak AG, et al. (2012) Modulation of the pHLIP transmembrane helix
insertion pathway. Biophys J 102(8):1846-1855.

25.

Weerakkody D, et al. (2013) Family of pH (low) insertion peptides for tumor
targeting. Proc Natl Acad Sci USA 110(15):5834-5839.

26.

Cruz-Monserrate Z, et al. (2014) Targeting Pancreatic Ductal Adenocarcinoma
Acidic Microenvironment. Sci Rep 4:4410.

179

27.

Adochite RC, et al. (2016) Comparative study of tumor targeting and
biodistribution of pH (low) insertion peptides (pHLIP peptides) conjugated
with different fluorescent dyes. Mol Imaging Biol 113(42):11829-11834.

28.

Onyango JO, et al. (2015) Noncanonical amino acids to improve the pH
response of pHLIP insertion at tumor acidity. Angew Chem Int Edit
54(12):3658-3663.

29.

Nguyen VP, Alves DS, Scott HL, Davis FL, & Barrera FN (2015) A novel
soluble peptide with pH-responsive membrane insertion. Biochemistry
54(43):6567-6575.

30.

Hunt JF, Rath P, Rothschild KJ, & Engelman DM (1997) Spontaneous, pHdependent membrane insertion of a transbilayer alpha-helix. Biochemistry
36(49):15177-15192.

31.

Cabaniss SE, Pugh KC, Pedersen LG, & Hiskey RG (1991) Proton, calcium,
and magnesium binding by peptides containing gamma-carboxyglutamic acid.
Int J Pept Prot Res 37(1):33-38.

32.

Shikamoto Y, Morita T, Fujimoto Z, & Mizuno H (2003) Crystal structure of
Mg2+- and Ca2+-bound Gla domain of factor IX complexed with binding
protein. J Biol Chem 278(26):24090-24094.

33.

Huang M, Furie BC, & Furie B (2004) Crystal structure of the calciumstabilized human factor IX Gla domain bound to a conformation-specific antifactor IX antibody. J Biol Chem 279(14):14338-14346.

34.

Barrera FN, et al. (2011) Roles of carboxyl groups in the transmembrane
insertion of peptides. J Mol Biol 413(2):359-371.
180

35.

Moshnikova A, Moshnikova V, Andreev OA, & Reshetnyak YK (2013) Antiproliferative effect of pHLIP-amanitin. Biochemistry 52(7):1171-1178.

36.

Weerakkody D, et al. (2016) Novel pH-sensitive cyclic peptides. Sci Rep
6:31322.

37.

Sharma GP, Reshetnyak YK, Andreev OA, Karbach M, & Müller G (2015)
Coil-helix transition of polypeptide at water-lipid interface. J Stat MechTheory E P01034.

38.

Kalafatis M, Egan JO, van't Veer C, & Mann KG (1996) Regulation and
regulatory role of gamma-carboxyglutamic acid containing clotting factors.
Crit Rev Eukaryot Gene Expr 6(1):87-101.

39.

Reshetnyak YK, Andreev OA, Lehnert U, & Engelman DM (2006)
Translocation of molecules into cells by pH-dependent insertion of a
transmembrane helix. Proc Natl Acad Sci USA 103(17):6460-6465.

40.

Burns KE & Thévenin D (2015) Down-regulation of PAR1 activity with a
pHLIP-based allosteric antagonist induces cancer cell death. Biochem J
472(3):287-295.

41.

Burns KE, McCleerey TP, & Thévenin D (2016) pH-selective cytotoxicity of
pHLIP-antimicrobial peptide conjugates. Sci Rep 6:28465.

42.

Shen C, et al. (2008) The protein fluorescence and structural toolkit: Database
and programs for the analysis of protein fluorescence and structural data.
Proteins 71(4):1744-1754.

43.

Schneider CA, Rasband WS, & Eliceiri KW (2012) NIH Image to ImageJ: 25
years of image analysis. Nat Methods 9(7):671-675.
181

TABLES
Table 1. The midpoint (pK), cooperativity (n), and time (t) parameters characterizing
the pH-dependent transition of pHLIP variants in the presence of POPC liposomes are
presented. EC20, EC50, and EC80 values were calculated for each pHLIP-amanitin
construct at physiological and low pH by analyzing the pH- and concentrationdependent cell viability data (Figure S2).

Peptide

EC20 (µM)
pH 7.4
pH 6.0
1.95
1.22

EC50 (µM)
pH 7.4
pH 6.0
1.37
0.56

EC80 (µM)
pH 7.4
pH 6.0
0.96
0.26

pK

n

t (s)

WT

6.5

1.8

36.8

WT/Gla

6.2

1.5

37.5

6.20

0.93

2.73

0.30

1.20

0.10

0.66

1.39

0.37

0.64

0.21

WT/Gla/Aad

6.6

1.4

34.8

3.01

PEG-2WT

6.6

1.8

18.8

1.98

0.54

1.03

0.19

0.53

0.07

PEG-4WT

6.6

2.2

13.1

0.473

0.19

0.33

0.11

0.23

0.06

Var3

5.7

0.9

0.9

10.63

1.30

3.95

0.43

1.47

0.14

1.34

2.76

0.50

1.48

0.19

Var3/Gla

6.3

0.7

0.7

5.12

Var3/GLL

6.6

0.4

0.1

1.75

0.47

0.91

0.23

0.47

0.11

ATRAM

6.4

0.9

0.1

2.06

0.40

1.23

0.22

0.74

0.12
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FIGURES
Figure 1. Schematic organization of pHLIP bundles: (a) PEG-2WT with 2 kDa 2-arm
PEG and two WT pHLIPs, and (b) PEG-4WT with 2 kDa 4-arm PEG and four WT
pHLIPs. Transitions between the three states of PEG-2WT and PEG-4WT in
phosphate buffer at pH 8 (State I), in the presence of POPC liposomes at pH 8 (State
II), and in the presence of liposomes at pH 4 (State III) were monitored by changes of
tryptophan fluorescence (c and d), circular dichroism (e and f), and oriented circular
dichroism (OCD) (g and h) signals. Normalized pH-dependent steady-state transitions
from State II to State III were examined by analyzing the shift in position of
fluorescence spectrum maximum of PEG-2WT (i) and PEG-4WT (j) in the presence
of physiological concentrations of calcium and magnesium ions. The data were fitted
using the Henderson-Hasselbalch equation; the fitting curves and 95% confidence
interval are shown by red and blue lines, respectively.
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Figure 2. Ellipticity ratios of CD signals at 205 nm to 222 nm are shown for pHLIP
variants in State I, II, and III (a). The values of ellipticity ratios are given in Table S3.
The therapeutic index (TI) was calculated for different pHLIP-amanitin constructs as
the ratio of EC50 at pH 7.4 to EC50 at pH 6.0 (b).
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Figure 3. pH-dependent potency was defined as the difference between cancer cell
viability when cells were incubated at pH 7.4 and pH 6.0 at varying concentrations of
different pHLIP-amanitin constructs. The WT-like group is shown in (a); the Var3like group and ATRAM are shown in (b).
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Figure 4. Normalized tumor fluorescence intensities of the AF546-pHLIP constructs
are shown; the signals were normalized by the tumor intensity of AF546-WT (a).
Tumor-to-muscle (T/M) (b), tumor-to-kidney (T/K) (c), and tumor-to-liver (T/L) (d)
fluorescence intensity ratios are shown. Statistically significant differences were
determined by two-tailed unpaired Student’s t-test, where * denotes p ≤0.05 and **
denotes p ≤0.005.
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Supplementary Materials and Methods
pHLIP characterization and pHLIP bundle synthesis. All peptides were purchased
from CS Bio Co. Peptides were characterized by reversed phase high-performance
liquid chromatography (RP-HPLC) using Zorbax SB-C18 and Zorbax SB-C8, 4.6 ×
250 mm, 5 μm columns (Agilent Technology). For biophysical measurements, PEG2WT and PEG-4WT were made by conjugating either 2 kDa bifunctional maleimidePEG-maleimide or 2 kDa 4-arm PEG-maleimide (Creative PEGWorks) to Cys-WT
via an N-terminal cysteine residue. Purification of the PEG-pHLIP constructs was
conducted using RP-HPLC. Peptide concentration was calculated by absorbance at
280 nm, where, for WT, WT/Gla, and WT/Gla/Aad, ε280 = 13,940 M-1 cm-1; for Var3,
Var3/Gla, and Var3/GLL, ε280 = 12,660 M-1 cm-1; and for ATRAM, ε280 = 5,690 M-1
cm-1. PEG construct concentration was presented in terms of peptide concentration,
not molecular concentration.
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Liposome preparation. Small unilamellar vesicles were used as model membranes
and were prepared by extrusion. 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine
(POPC; Avanti Polar Lipids) was dissolved in chloroform at a concentration of 12.5
mg/mL, then desolvated by rotary evaporation for two hours under vacuum. The
resulting POPC film was rehydrated in 10 mM phosphate buffer at pH 8, either with
additional calcium and magnesium ions (1.25 mM calcium and 0.65 mM magnesium),
or without additional ions, vortexed, and extruded fifteen times through a membrane
with a pore size of 50 nm.

Steady-state fluorescence measurements. Steady-state fluorescence spectra were
measured using a PC1 spectrofluorometer (ISS) with temperature control set to 25.0
°C. The tryptophan fluorescence was excited using an excitation wavelength of 295
nm. Excitation and emission slits were set to 8 nm, and excitation and emission
polarizers were set to 54.7° and 0.0°, respectively. Sample preparation was conducted
24 hours prior to experiments to allow for State II equilibration. A buffer-only sample
was used as a baseline for State I, and a buffer-with-POPC-only sample was used as a
baseline for States II and III.

pH dependence measurements. Measurements of pH dependence were taken with
the PC1 spectrofluorometer by using the shift in the position of maximum of peptide
fluorescence as an indication of changes of the peptide environment at varying pH. All
pH

dependence

measurements

were

conducted

using

blood

physiological

concentrations of free calcium and magnesium ions (1.25 and 0.65 mM, respectively).
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After the addition of hydrochloric acid, the pH of solutions containing 5 µM peptide
and 1 mM POPC were measured using an Orion PerHecT ROSS Combination pH
Micro Electrode and an Orion Dual Star pH and ISE Benchtop Meter (Thermo Fisher
Scientific) before and after spectrum measurement to ensure equilibration. The
tryptophan fluorescence spectrum at each pH was recorded, and the spectra were
analyzed using the Protein Fluorescence and Structural Toolkit (PFAST) (42) to
determine the positions of spectral maxima (𝜆max ). The position of 𝜆max was plotted
as a function of pH and normalized, such that 𝜆initial
max − position of spectral maximum
in State II was set to 1 and 𝜆final
max − position of spectral maximum in State III, was set
to 0. The normalized pH-dependence was fit with the Henderson-Hasselbach equation
(using OriginLab software) to determine the cooperativity (𝑛) and transition mid-point
(p𝐾) of transition of the peptide population from State II to State III:

1

𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 𝑝𝐻 𝑑𝑒𝑝𝑒𝑛𝑑𝑒𝑛𝑐𝑒 = 1+10𝑛(pH−p𝐾)

(1)

Steady-state circular dichroism and oriented CD measurements. Steady-state CD
was measured using an MOS-450 spectrometer (Bio-Logic Science Instruments) in the
range of 190 to 260 nm with a step size of 1 nm, and with temperature control set to
25.0 °C. Samples were prepared 24 hours prior to experiments to allow for State II
equilibration. A buffer-only sample was used as baseline for State I, and a buffer-withPOPC-only sample was used as baseline for States II and III.
OCD was measured using supported planar POPC bilayers prepared using a
Langmuir-Blodgett system (KSV Nima). Fourteen quartz slides with 0.2 mm spacers
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were used; after sonicating the slides in 5% cuvette cleaner (Contrad 70; Decon Labs)
in deionized water (≥18.2 MΩ cm at 25 °C; Milli-Q Type 1 Ultrapure Water System,
EMD Millipore) for fifteen minutes and rinsing with deionized water, the slides were
immersed and sonicated for ten minutes in 2-propanol, sonicated again for ten minutes
in acetone, sonicated a final time in 2-propanol for ten minutes, and rinsed thoroughly
with deionized water. Lastly, the slides were immersed in a 3:1 solution of sulfuric
acid to hydrogen peroxide for five minutes and rinsed three times in deionized water.
The slides were stored in deionized water until they were used. POPC bilayers were
deposited on the fourteen slides using a Langmuir-Blodgett minitrough: a 2.5 mg/mL
solution of POPC in chloroform was spread on the subphase (deionized water) and the
chloroform was allowed to evaporate for fifteen minutes, after which the POPC
monolayer was compressed to 32 mN/m. A lipid monolayer was deposited on the
slides by retrieving them from the subphase, after which a solution of 10 µM peptide
and 500 µM of 50 nm POPC liposomes at pH 4 was added to the slides, resulting in
the creation of the supported bilayer by fusion between the monolayer on the slides
and the peptide-laden lipid vesicles. After incubation for six hours at 100% humidity,
the slides were rinsed with buffer solution to remove excess liposomes, and the spaces
between the cuvettes were filled with buffer at pH 4. Measurements were taken at
three points during the experiment: immediately after the addition of the peptide/lipid
solution (0 h), after the slides were rinsed to remove excess liposomes following the
six-hour incubation time (6 h), and after an additional twelve-hour incubation time and
rinse with buffer (18 h); these measurements were recorded on the MOS-450
spectrometer with sampling times of two seconds at each wavelength. Control
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measurements were conducted using a peptide solution between slides without
supported bilayers and in the presence of POPC liposomes.

Kinetics measurements. Stopped-flow fluorescence measurements were made using
an SFM-300 mixing system (Bio-Logic Science Instruments) in conjunction with the
MOS-450 spectrometer. All solutions were degassed for fifteen minutes prior to
loading into the stopped-flow system. pHLIP variants were incubated with POPC for
24 hours prior to the experiment to reach State II equilibrium, and insertion was
induced by mixing equal volumes of pHLIP/POPC solutions with hydrochloric acid
diluted to ensure a pH drop from pH 8 to pH 4. Kinetics data were fit by one-, two-,
three-, or four-state exponential models in OriginLab.

Amanitin pHLIP conjugates. α-amanitin (Sigma-Aldrich) was conjugated to
succinimidyl 3-(2-piridyldithio)propionate) (SPDP; Thermo Fisher Scientific),
followed by purification and conjugation of the SPDP-amanitin to the C-terminal
cysteine residues of pHLIP peptides. For synthesis of PEG-2WT-amanitin and PEG4WT-amanitin, Lys-WT-Cys with N-terminal lysine and C-terminal cysteine residues
was used, and the Lys-WT-SPDP-amanitin was conjugated to dibenzocyclooctynesulfo-N-hydroxysuccinimidyl ester (DBCO-NHS ester; Sigma-Aldrich), resulting in
DBCO-WT-SPDP-amanitin.

Finally,

2-arm

or

4-arm

PEG-azide

(Creative

PEGWorks) was conjugated to DBCO-WT-SPDP-amanitin, resulting in PEG-DBCOWT-SPDP-amanitin, with a cleavable disulfide bond present in SPDP, between the
peptide and amanitin cargo. Construct concentration was calculated by absorbance at
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310 nm, where, for α-amanitin, ε310 = 13,000 M-1 cm-1. Construct concentration was
presented in terms of peptide/amanitin concentration. Purification was conducted
using RP-HPLC. Zorbax SB-C18 columns (9.4 × 250 mm, 5 µm; Agilent
Technologies) were used for all peptide-amanitin conjugates other than ATRAMamanitin, PEG-2WT-amanitin, and PEG-4WT-amanitin, for which Zorbax SB-C8
columns (9.4 × 250 mm, 5 µm; Agilent Technologies) were used.

Cell proliferation assay. Human cervix adenocarcinoma cells (HeLa; American Type
Culture Collection) were authenticated, stored according to the instructions of the
supplier, and used within three months of frozen aliquot resuscitation. Cells were
cultured in Dulbecco’s modified Eagle’s medium (DMEM; Sigma-Aldrich) at pH 7.4
with 4.5 g/L D-glucose, supplemented with 10% heat-inactivated fetal bovine serum
(FBS; Sigma-Aldrich) and 10 µg/mL ciprofloxacin (Sigma-Aldrich), in a humidified
atmosphere of 5% CO2 and 95% air at 37 °C. The pH 6.0 medium was prepared by
mixing 13.3 g of dry DMEM in 1 L of deionized water. HeLa cells were loaded in the
wells of 96-well plates (5,000 cells/well) and incubated overnight. The standard
growth medium was replaced with medium without FBS, at pH 6.0 or 7.4, containing
increasing amounts of pHLIP-amanitin conjugates (from 0 to 2.0 µM). Treatment with
amanitin alone for two hours and at concentrations up to 2 µM does not induce cell
death (35). After two-hour incubation with the pHLIP-amanitin conjugates, the
constructs were removed and replaced with standard growth medium. Cell viability
was assessed after 48 hours using the CellTiter 96 AQueous One Solution Cell
Proliferation Assay (Promega); the colorimetric reagent was added to cells for one
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hour, followed by absorption measurement at 490 nm. All samples were prepared in
triplicate, and each experiment was repeated between 3 and 6 times. All obtained cell
proliferation data were normalized by corresponding controls (non-treated cells).
There was no difference in the viability of cells incubated with media, without
construct, at pH 7.4 and pH 6.0; therefore, the role of pH was excluded from the
consideration. Normalized cell viability data obtained in different experiments were
averaged and presented in terms of the logarithm of dose of pHLIP-amanitin
constructs. The dose-response function was used for fitting the obtained data (Figure
S2) (OriginLab):

𝐴 −𝐴

𝑡
𝑏
𝐶𝑒𝑙𝑙 𝑉𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 = 𝐴𝑏 + 1+10𝑝(log
𝑥0 −𝑥)

(2)

where 𝐴𝑏 and 𝐴𝑡 are the bottom and the top asymptotes, respectively. The top
asymptote was set as constant (100%) while for the bottom asymptote we allowed
small variations in the range of 0 to 10%. 𝑝 is the slope (cooperativity parameter) and
log 𝑥0 is the center of the transition (i.e., the concentration for half response) which is
used to calculate the EC20, EC50, EC80 values:

𝐸𝐶20 = 10(log 𝑥0 +

log 0.25⁄
𝑝)

(3)

𝐸𝐶50 = 10log 𝑥0

𝐸𝐶80 = 10(log 𝑥0 +

(4)

log 4⁄
𝑝)

(5)
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Therapeutic index (TI) was calculated according to the equation:

𝑇𝐼 =

p𝐻 7.4

𝐸𝐶50

(6)

p𝐻 6.0

𝐸𝐶50

Additionally, the cytotoxicity of the PEG-2WT and PEG-4WT constructs without
amanitin was tested: these experiments demonstrated no cytotoxicity at physiological
or low pH at treatment concentrations up to 10 µM.

Fluorescent pHLIP conjugates. Alexa Fluor 546 (AF546) C5 maleimide (Thermo
Fisher Scientific) was conjugated to the N-terminal cysteine residues of WT, Var3,
Var3/Gla, and ATRAM. AF546 NHS Ester (Thermo Fisher Scientific) was conjugated
to the N-terminal lysine residues of WT/Gla, WT/Gla/Aad, and Var3/GLL. For PEG2WT and PEG-4WT, Cys-WT-Lys, with N-terminal cysteine and C-terminal lysine
residues, was used, and was first conjugated to 2-arm maleimide-PEG-maleimide or 4arm PEG-maleimide resulting in PEG-WT-Lys. Then, AF546 NHS Ester was
conjugated to the C-terminal lysine residue, resulting in 2-arm and 4-arm PEG-pHLIP
constructs with C-terminal AF546 fluorophores. Construct concentration was
calculated by absorbance at 554 nm, where, for AF546, ε554 = 93,000 M-1 cm-1.
Construct concentration was presented in terms of AF546/peptide concentration, not
molecular concentration. Purification was conducted using RP-HPLC for all peptides
other than PEG-4WT-AF546, which was purified via Amicon Ultra MWCO 10 kDa
centrifugal filter (Sigma-Aldrich). Zorbax SB-C18 columns (9.4 × 250 mm, 5 µm;
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Agilent Technologies) were used for all AF546-peptide conjugates except AF546ATRAM and PEG-2WT-AF546, for which Zorbax SB-C8 columns (9.4 × 250 mm, 5
µm; Agilent Technologies) were used.

Ex vivo imaging. All animal studies were conducted according to the animal protocol
AN04-12-011 approved by the Institutional Animal Care and Use Committee at the
University of Rhode Island, in compliance with the principles and procedures outlined
by the National Institutes of Health for the care and use of animals. Mouse mammary
cells (4T1; American Type Culture Collection) were subcutaneously implanted in the
right flank (8 × 105 cells/0.1 mL/flank) of adult female BALB/cAnNHsd mice
(Envigo). When tumors reached approximately 5-6 mm in diameter, single tail vein
injections of 100 µL, 40 µM fluorophore-pHLIP solutions in PBS were performed.
Mice were euthanized 4 or 24 hours after injection, and necropsy was immediately
performed. Tumors and major organs were cut in half and imaged using an FX Kodak
in-vivo image station connected to an Andor CCD camera. Mean surface fluorescence
intensity of tumor, tissue and organs was obtained via analysis of fluorescence images
in ImageJ (NIH) (43). The corresponding autofluorescence signal was subtracted to
obtain the net fluorescence intensities used in the study. Autofluorescence was
calculated after imaging tumors, tissue, and organs collected from mice with no
injection of fluorescent pHLIP constructs.
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SUPPLEMENTARY TABLES
Table S1. List of pHLIP sequences used in the study.

Peptide

Sequence

Cys-WT

ACEQNPIYWARYADWLFTTPLLLLDLALLVDADEGT

WT-Cys

AEQNPIYWARYADWLFTTPLLLLDLALLVDADEGCT

Lys-WT-Cys

Ac-AKEQNPIYWARYADWLFTTPLLLLDLALLVDADECT

Lys-WT/Gla-Cys

Ac-AKEQNPIYWARYAGlaWLFTTPLLLLDLALLVDADECT

Lys-WT/Gla/Aad-Cys

Ac-AKEQNPIYWARYAGlaWLFTTPLLLLAadLALLVDADECT

Cys-Var3

ACDDQNPWRAYLDLLFPTDTLLLDLLWA

Var3-Cys

ADDQNPWRAYLDLLFPTDTLLLDLLWCA

Cys-Var3/Gla

ACDDQNPWRAYLGlaLLFPTDTLLLDLLWG

Var3/Gla-Cys

ADDQNPWRAYLGlaLLFPTDTLLLDLLWCG

Lys-Var3/GLL-Cys
Cys-ATRAM

Ac-GKEEQNPWLGAYLDLLFPLELLGLLELGLWCG
ACGLAGLAGLLGLEGLLGLPLGLLEGLWLGLELEGN

ATRAM-Cys

GLAGLAGLLGLEGLLGLPLGLLEGLWLGLELEGNCA
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Table S2. Molecular weights (MW) of peptides, and retention times and
corresponding percentages of acetonitrile at elution for 30 min method of 25-80%
gradient of acetonitrile/0.05% TFA in water/0.05% TFA used in C18 and C8 columns.
†

Peptide eluted during washing with acetonitrile, after the completion of the gradient.

Peptide

MW (Da)

Zorbax SB-C18
(4.6 × 250 mm, 5 µm)
Retention
% Acetonitrile
Time (min)
21.6
64.6%

Zorbax SB-C8
(4.6 × 250 mm, 5 µm)
Retention
% Acetonitrile
Time (min)
20.6
62.8%

Cys-WT

4111.7

Lys-WT-Cys

4224.9

21.6

64.6%

20.4

62.4%

Lys-WT/Gla-Cys

4283.1

22.3

65.9%

21.2

63.9%

Lys-WT/Gla/Aad-Cys

4310.9

22.8

66.8%

21.7

64.8%

Cys-Var3

3292.8

19.7

61.1%

19.6

60.9%

Cys-Var3/Gla

3333.8

19.9

61.5%

19.7

61.1%

Lys-Var3/GLL-Cys

3643.2

28.0

76.2%

26.0

72.7%

93.0%

27.2

74.9%

Cys-ATRAM

3516.2

30.6

†
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Table S3. Positions of maxima of tryptophan fluorescence spectra (λmax) and ratios of
ellipticity at 205 nm to 222 nm of pHLIP constructs in States I, II, and III are given.

λmax (nm)

Construct

Ellipticity at 205/222 nm

State I

State II

State III

State I

State II

State III

WT

351.6

347.4

340.0

1.61

2.16

0.68

WT/Gla

348.2

347.1

338.2

2.02

1.60

0.70

WT/Gla/Aad

347.5

346.7

338.3

1.60

1.31

0.68

PEG-2WT

341.8

341.2

336.6

1.12

1.48

0.71

PEG-4WT

344.0

343.4

338.9

1.18

1.07

0.71

Var3

350.2

346.8

339.9

2.35

1.55

0.71

Var3/Gla

351.4

345.7

339.2

2.72

1.76

0.85

Var3/GLL

349.3

343.3

341.2

2.21

1.32

0.84

ATRAM

345.5

341.4

333.0

2.45

1.44

0.85
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Table S4. Fluorescence intensity obtained by ex vivo imaging of tumor, tissue, and
organs 4 hours after a single IV administration of the Alexa Fluor 546-pHLIP
constructs (data obtained at 24 hours post-injection are shown for PEG-2WT and
PEG-4WT). Values of tissue autofluorescence are provided in the last row. Sample
size (n) is given in the last column for each construct.

Total Fluorescence Intensity in tumor, muscle and organs (a.u.)
Construct
Tumor

Muscle

Kidney

Liver

Lungs

Spleen

n

WT

2335.7 ± 447.1

726.8 ± 58.5

988.5 ± 91.0

998.7 ± 142.0

545.8 ± 32.6

447.0 ± 31.7

5

WT/Gla

1372.1 ± 331.7

591.2 ± 73.2

880.2 ± 126.5

1102.1 ± 239.6

456.2 ± 68.6

387.9 ± 63.3

13

WT/Gla/Aad

1336.6 ± 304.5

559.6 ± 53.5

726.6 ± 149.9

1156.4 ± 120.8

448.5 ± 79.9

374.1 ± 45.0

13

PEG-2WT

1443.4 ± 178.5

545.3 ± 42.2

602.7 ± 79.2

1267.1 ± 146.2

462.0 ± 28.5

450.7 ± 17.3

5

PEG-4WT

912.8 ± 159.5

495.5 ± 23.0

523.4 ± 52.5

1209.7 ± 100.7

431.0 ± 54.9

403.7 ± 30.0

7

Var3

3474.3 ± 924.2

760.7 ± 68.3

1263.9 ± 136.5

904.8 ± 93.4

564.3 ± 130.1

335.6 ± 45.0

7

Var3/Gla

2948.9 ± 540.6

889.3 ± 144.7

1390.0 ± 247.5

702.9 ± 140.9

784.5 ± 248.7

379.2 ± 47.8

5

Var3/GLL

1577.9 ± 364.2

694.2 ± 27.5

1690.8 ± 431.8

1194.3 ± 147.1

520.2 ± 18.6

442.8 ± 37.4

5

ATRAM

3039.5 ± 620.9

813.3 ± 105.4

1009.8 ± 183.9

1073.2 ± 146.3

716.6 ± 109.0

421.3 ± 35.3

9

PEG-2WT (24 h)

894.9 ± 151.8

486.3 ± 19.8

525.1 ± 37.6

753.6 ± 54.0

547.2 ± 64.8

346.3 ± 11.0

5

PEG-4WT (24 h)

663.5 ± 121.1

440.1 ± 7.7

464.2 ± 35.1

726.7 ± 69.6

482.8 ± 48.5

331.8 ± 4.4

5

Autofluorescence

426.9 ± 15.7

402.7 ± 11.5

325.6 ± 30.8

354.7 ± 28.3

392.7 ± 32.7

296.1 ± 23.2

12
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Table S5. Tumor-to-muscle (T/M), tumor-to-kidney (T/K), and tumor-to-liver (T/L)
ratios presented in Figures 4b, 4c, and 4d, respectively.

Construct
WT

T/M
5.87 ± 0.64

T/K
2.95 ± 0.95

T/L
3.03 ± 0.76

WT/Gla

5.39 ± 1.65

1.77 ± 0.68

1.40 ± 0.76

WT/Gla/Aad

6.54 ± 3.15

2.59 ± 1.33

1.14 ± 0.37

PEG-2WT

7.48 ± 1.86

3.80 ± 0.77

1.13 ± 0.19

PEG-4WT

5.34 ± 1.53

2.55 ± 0.78

0.57 ± 0.17

Var3

8.86 ± 3.61

3.38 ± 1.34

5.62 ± 1.90

Var3/Gla

5.30 ± 0.89

2.46 ± 0.64

8.29 ± 4.19

Var3/GLL

4.03 ± 1.54

0.87 ± 0.23

1.42 ± 0.55

ATRAM

6.56 ± 1.55

3.96 ± 1.05

3.72 ± 1.01
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Table S6. The membrane-inserted populations of different pHLIP variants were
calculated using the pH dependence parameters pK and n (Table 1).

pH

WT

WT/Gla

WT/Gla/Aad

PEG-2WT

PEG-4WT

Var3

Var3/Gla

Var3/GLL

ATRAM

7.4

2%

2%

7%

4%

2%

3%

15%

32%

11%

7.2

5%

3%

13%

8%

5%

4%

19%

37%

16%

7.0

11%

6%

22%

16%

12%

6%

24%

41%

22%

6.8

22%

11%

34%

30%

27%

9%

31%

45%

30%

6.5

50%

26%

58%

60%

62%

16%

42%

52%

45%

6.2

78%

50%

78%

84%

88%

26%

54%

59%

60%

6.0

89%

67%

87%

92%

95%

35%

62%

63%

70%

202

Fig. S1. Three-state tryptophan fluorescence (A and D), circular dichroism (B and E),
and pH dependence plots (C and F) are shown for Var3/Gla (A-C) and Var3/GLL (DF) pHLIP variants. Transitions between the three folding states of Var3/Gla and
Var3/GLL pHLIP variants in phosphate buffer at pH 8 (State I), in the presence of
POPC liposomes at pH 8 (State II), and in the presence of liposomes at pH 4 (State III)
were monitored by changes of tryptophan fluorescence (A and D), and circular
dichroism (B and E) signals. pH-dependent steady-state transitions from State II to
State III were examined by analyzing the shift of the position of tryptophan
fluorescence spectrum maxima of Var3/Gla (C) and Var3/GLL (F) constructs in the
presence of physiological concentrations of calcium and magnesium ions. The data
were fitted using the Henderson–Hasselbalch equation; the fitting curves and 95%
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Fig. S2. Cell viability data were obtained after treatment of HeLa cells with pHLIPamanitin constructs for 2 hours at pH 7.4 and pH 6.0, followed by removal of the
constructs, transferal of cells to normal cell culture media, and assessment of cell
death at 48 hours by MTS assay.
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